Fatiga Suprarrenal

1-Deoxynojirimycin (DNJ) is a potent alpha-glucosidase inhibitor found in mulberry leaves (Morus alba), used in traditional Chinese and Japanese medicine. A 2024 systematic review and meta-analysis found DNJ significantly reduced postprandial plasma glucose and insulin AUC in individuals with impaired glucose tolerance and T2DM.

4-Hydroxyisoleucine is a unique non-protein amino acid found almost exclusively in fenugreek seeds. It directly stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. Multiple in vitro and in vivo studies confirm its insulinotropic and insulin-sensitizing effects.

Multiple randomized controlled trials show that acacia gum supplementation (typically 30 g/day for 8–12 weeks) significantly reduces fasting plasma glucose and HbA1c in type 2 diabetic patients. A crossover RCT in healthy adults also showed lowered peak postprandial blood glucose with 20 g acacia gum. The proposed mechanism is slowed glucose absorption due to soluble fiber.

Human pilot data show acai berry consumption reduces fasting glucose, fasting insulin, and post-prandial glucose excursions in overweight adults. These findings are from a small, uncontrolled study and require confirmation in larger RCTs. The proposed mechanism involves antioxidant reduction of oxidative stress in metabolic pathways.

Adzuki bean has a low glycemic index (~26–35) and contains polyphenols that inhibit α-glucosidase, slowing glucose absorption. One RCT in 120 T2D patients found extruded adzuki bean convenience food produced glycemic outcomes equivalent to a conventional low-GI diet. Animal studies consistently show reduced fasting blood glucose and improved glucose tolerance, though robust human RCT data remain limited.

Agar has been shown in a 12-week RCT to significantly reduce HbA1c and fasting glucose in obese patients with impaired glucose tolerance or type 2 diabetes. A separate human study examined agar's effect on postprandial glycaemic profiles. Evidence is limited to small trials but indicates a fiber-mediated attenuation of glucose excursions.

Multiple preclinical studies demonstrate antihyperglycaemic, insulin-releasing, and alpha-glucosidase inhibitory activities in agrimony. A classic study by Gray and Flatt (1998) showed agrimony countered hyperglycaemia in STZ-diabetic mice and stimulated insulin secretion in vitro. Alpha-glucosidase inhibition across five Agrimonia species has been confirmed. No human RCT specifically in diabetes exists.

Several preclinical studies document antidiabetic effects of ajwain extract, including inhibition of alpha-glucosidase and improvements in blood glucose in diabetic animal models. Thymol and carvacrol are proposed as active constituents. Human clinical trials are absent, but the pharmacological evidence is sufficient to classify as scientific at the pre-clinical level.

Multiple human studies link higher Akkermansia muciniphila abundance to better glycemic control, with a randomized controlled trial in overweight/obese insulin-resistant adults demonstrating significant reductions in fasting insulin. A. muciniphila produces propionate and the secreted protein P9, both of which stimulate GLP-1 secretion from intestinal L-cells to modulate postprandial glucose. A phase 2 multicenter RCT in drug-naïve T2D patients further showed that supplementation improved insulin sensitivity and reduced insulinemia.

Population data associate higher ALA intake with modestly reduced type 2 diabetes risk. However, RCT meta-analyses find no consistent ALA effect on fasting blood glucose, HbA1c, or HOMA-IR in diabetic patients. The relationship is mechanistically plausible but clinically mixed.

Alpha-lipoic acid (ALA) is an endogenous antioxidant that has been clinically evaluated for improving insulin sensitivity in T2DM and managing diabetic neuropathy. Multiple clinical trials support modest improvements in insulin sensitivity and fasting glucose. It is also well-studied for reducing HOMA-IR.

Alfalfa has a traditional role as an antidiabetic agent and there is limited human evidence supporting acute postprandial glucose reduction. Animal studies consistently show blood glucose lowering. One small human study in type II diabetic patients demonstrated significant reductions in 2-hour postprandial glucose with 8 g of alfalfa leaf powder.

Multiple human clinical trials demonstrate that calcium alginate and sodium alginate reduce postprandial blood glucose levels. The mechanism involves inhibition of α-glucosidase and maltase activity, slowing starch digestion. Evidence spans healthy adults and type 2 diabetic populations.

Clinical evidence supports a modest improvement in glycemic markers with regular almond consumption, particularly in high-risk or Asian Indian populations. Almonds reduce postprandial glucose response when eaten with meals and have been shown to lower HbA1c in pre-diabetic young adults. However, findings are inconsistent across populations, with at least one RCT reporting adverse effects on insulin sensitivity when almonds were not used as a substitute for other foods.

Aloe vera gel has demonstrated blood glucose-lowering effects in multiple RCTs in prediabetic and early-stage diabetic patients. A meta-analysis of 5 RCTs (415 participants) found aloe vera significantly reduced FBG by 30 mg/dL and HbA1c by 0.41% versus placebo. It also improved lipid profiles.

Isoquercitrin (the direct metabolic precursor of AGIQ) has been shown in a clinical study to promote pancreatic islet function, improve glucose tolerance, and help regulate blood glucose levels. Quercetin, AGIQ's ultimate metabolite, has documented anti-diabetic mechanisms including alpha-glucosidase inhibition and insulin sensitization.

Multiple animal studies demonstrate that A. galanga extracts reduce fasting blood glucose in streptozotocin- and alloxan-induced diabetic rodent models. The flavonoid galangin has been shown to lower glucose, triglycerides, and plasma insulin in fructose-fed rats, suggesting insulin-sensitising properties. Human clinical evidence remains limited.

Amaranth seeds, leaves, and extracts have been investigated for antidiabetic effects across multiple study types. Bioactive peptides from amaranth protein hydrolysates inhibit DPP-IV and alpha-glucosidase enzymes involved in glucose metabolism. A 2025 Frontiers in Nutrition observational study found reductions in fasting blood glucose and HbA1c over three months with an Amaranthus caudatus extract. Amaranth fiber also slows carbohydrate absorption, contributing to lower postprandial glucose.

Clinical and epidemiological research consistently links endogenous amylase activity to glycemic control. Low serum amylase is associated with elevated blood glucose, insulin resistance, and type 2 diabetes. Animal studies show exogenous amylase supplementation can lower postprandial blood glucose and modulate insulin secretion, though robust human intervention trials remain limited.

Amylopectin's highly branched structure presents a large surface area to digestive enzymes, resulting in rapid hydrolysis and fast glucose absorption, which produces sharp postprandial blood glucose and insulin spikes compared to amylose-rich starches. Human and animal studies confirm that higher amylopectin-to-amylose ratios in the diet correlate with higher glycemic index values. Chronic high amylopectin intake has been linked to greater insulin resistance in animal models, raising relevance for blood sugar management.

Human clinical studies show that Andrographis supplementation can lower HbA1c and fasting insulin in type 2 diabetic patients. An open-label trial in 20 T2DM patients found a 5.46% reduction in HbA1c (p<0.01) with escalating doses over 12 weeks. A separate clinical study of a combined Andrographis/Syzygium polyanthum extract in metformin-treated T2DM patients demonstrated improvements in fasting and postprandial glucose.

Multiple preclinical studies demonstrate significant hypoglycemic activity from several anemarrhena constituents including mangiferin, polysaccharides (anemarans A–D), and timosaponin derivatives. Mangiferin has been shown to lower blood glucose in type-2 diabetic mouse models by reducing insulin resistance. The extract also stimulates insulin secretion from isolated pancreatic islets.

A 24-week randomized, double-blind, placebo-controlled trial in 110 type 2 diabetics found that 250 mg/day of annatto-derived delta-tocotrienol significantly reduced fasting blood glucose (6.8%), insulin (7.6%), and HOMA-IR (13.1%). Animal studies also show annatto tocotrienols improve glucose homeostasis and insulin tolerance. The mechanism likely involves reduction of oxidative stress and inflammation that impair insulin signaling.

Epidemiological studies associate regular apple consumption with reduced risk of type 2 diabetes. Apple polyphenols, particularly phloridzin and quercetin, may modulate glucose absorption and insulin signaling. However, RCT evidence for blood glucose lowering is mixed, with more consistent effects seen in higher-risk populations.

Multiple meta-analyses of controlled clinical trials demonstrate that ACV significantly reduces fasting blood glucose and HbA1c in adults with type 2 diabetes. The primary mechanism involves acetic acid inhibiting disaccharidase activity in the small intestine, slowing starch digestion and blunting postprandial glycemia. Evidence is graded moderate quality for fasting blood sugar outcomes.

Apricots have a low glycemic index and contain soluble fiber that slows carbohydrate absorption. Polyphenols including chlorogenic acid and quercetin have demonstrated glucoregulatory properties. Animal studies show apricot kernel administration significantly reduces blood glucose and glycated hemoglobin in diabetic models. Human clinical evidence is limited but supportive at a nutritional level.

Multiple human studies demonstrate that Aronia melanocarpa supplementation reduces fasting blood glucose and postprandial glucose levels. A systematic review quantified a mean reduction in blood glucose of 0.44 mmol/L (p=0.0001) versus control. One randomized controlled trial also found daily Aronia juice reduced postprandial glucose (β = −3.03, p<0.01). Evidence is promising but overall RCT evidence remains inconsistent.

A meta-analysis of nine RCTs found artichoke supplementation significantly reduced fasting blood glucose (WMD: −5.28 mg/dL, p=0.005). Chlorogenic acid inhibits glucose-6-phosphatase and modulates gluconeogenesis, while inulin slows gastric emptying and glucose absorption. A subgroup analysis showed artichoke alone (not co-supplemented) also significantly reduced HOMA-IR.

Multiple animal studies and a small human pilot study support ashitaba's antidiabetic activity. Its chalcones inhibit α-glucosidase more potently than the drug acarbose in vitro, suppress post-meal glucose spikes in mouse models, and a human metabolic syndrome pilot confirmed anti-diabetic mellitus efficacy. No large-scale RCTs have been conducted.

Multiple clinical studies and systematic reviews indicate ashwagandha lowers fasting blood glucose and HbA1c in diabetic and pre-diabetic subjects. Active withanolides inhibit alpha-glucosidase and DPP-4 enzymes and activate AMPK, suppressing hepatic gluconeogenesis. Evidence is promising but most trials are small and short-term.

Asparagus officinalis extracts have shown hypoglycemic activity in multiple animal models, including streptozotocin-induced diabetic rats, by improving insulin secretion and beta-cell function. A small open clinical trial in humans found that powdered asparagus bottom-stems and cladophylls (6 g/day for 10 weeks) significantly reduced fasting plasma glucose. Human clinical evidence remains limited and preliminary.

Multiple RCTs and a 2026 meta-analysis of 6 RCTs (n=292) demonstrate astaxanthin significantly reduces fasting blood glucose (WMD: −16.1 mg/dL) and HbA1c in prediabetes and type 2 diabetes patients. A 12-week double-blind RCT (n=53) showed improved 2-hour glucose on OGTT and improved Matsuda insulin sensitivity index. The mechanism involves reduction of oxidative stress and inflammation that impair insulin signaling.

A 2024 meta-analysis of 20 RCTs (953 adults with T2DM) found astragalus added to metformin reduced fasting blood glucose and HbA1c more than metformin alone, though most included studies were low quality. Active constituents (polysaccharides, saponins, flavonoids) activate AMPK and PPAR-gamma pathways in liver and skeletal muscle to improve glucose metabolism. Astragalus is the most frequently prescribed herb for diabetes management in China.

Polysaccharides from Atractylodes macrocephala (AMP) have been shown in multiple preclinical models to reduce fasting and postprandial blood glucose. Mechanisms include protecting islet beta-cells, improving insulin sensitivity, and promoting peripheral glucose utilization. Human clinical data remain limited.

Bamboo shoot dietary fiber and polysaccharides have demonstrated hypoglycemic activity in multiple animal models. Bamboo shoot polysaccharides reduced blood glucose by up to 48.7% and improved insulin sensitivity in diabetic mice. BEX also improved glucose tolerance and inhibited hyperinsulinemia in obese mouse models.

Banaba (Lagerstroemia speciosa) leaf has been used as a traditional anti-diabetic remedy in the Philippines for centuries. Scientific studies confirm its hypoglycemic effects are primarily mediated by corosolic acid and ellagitannins. Human trials show 12–30% reductions in blood glucose with banaba extract supplementation.

Green/unripe bananas are rich in resistant starch and have a low glycemic index (GI ~47), which moderates postprandial glucose and insulin responses. Native banana starch (NBS) supplementation in clinical trials improved insulin sensitivity and reduced fasting glycemia in obese and diabetic subjects. Ripeness markedly affects glycemic impact.

Multiple human RCTs demonstrate that baobab fruit powder/extract reduces postprandial blood glucose when consumed alongside carbohydrate-rich foods. The Oxford Brookes University study (Coe et al., Nutrition Research, 2013) found significant reductions at both 18.5 g and 37 g doses compared with control. A 2022 Portuguese RCT (NCT05140629) in 31 healthy adults confirmed significantly lower glycemic incremental AUC (p=0.012) and peak glucose concentration (p=0.029) after baobab aqueous extract versus control following an OGTT. The mechanism involves polyphenol-driven inhibition of starch-digesting enzymes and high soluble fiber slowing glucose absorption.

Multiple RCTs and meta-analyses demonstrate that Berberis vulgaris and its alkaloid berberine significantly reduce fasting blood glucose, post-meal glucose, and HbA1c in patients with type 2 diabetes and metabolic syndrome. The primary mechanism is AMPK activation, which mimics the action of metformin. A direct barberry RCT in 80 T2DM patients showed significant improvements in fasting blood sugar, fructosamine, and HOMA-IR.

Barley's soluble β-glucan forms a viscous gel in the gut that slows glucose absorption and blunts postprandial glycemic spikes. Both the FDA and EFSA have approved health claims for barley β-glucan and reduction of postprandial blood glucose. Multiple RCTs and reviews confirm consistent postprandial glucose-lowering effects.

Icariin inhibits α-glucosidase enzyme activity—a mechanism directly relevant to postprandial blood glucose control—and has demonstrated glucose-lowering effects in multiple diabetic animal models. It also modulates glucose/lipid metabolism and insulin signaling pathways. Evidence is predominantly preclinical; human glycemic trials are not yet established.

Multiple clinical trials, including a 2024 RCT (n=200) and a 2017 systematic review of 24 studies, show that basil (particularly holy basil/tulsi) significantly reduces fasting blood glucose and HbA1c in type 2 diabetes patients. Active constituents eugenol and ursolic acid are thought to improve insulin sensitivity and inhibit carbohydrate-digesting enzymes. Evidence quality is limited by small studies and short durations.

Bee pollen contains polyphenols and flavonoids that inhibit alpha-glucosidase and alpha-amylase, key enzymes in carbohydrate digestion, potentially lowering postprandial blood glucose. A small human trial in type 2 diabetics showed significant reduction in HbA1c. Animal evidence is strong, though robust human RCTs are limited.

Human RCT evidence indicates beetroot juice can reduce postprandial glucose and insulin responses and improve oral glucose tolerance, particularly in type 2 diabetes. Mechanisms include nitrate-mediated enhancement of insulin sensitivity and betalain inhibition of advanced glycation end-product (AGE) formation.

Animal and in vitro studies document that belleric myrobalan extracts and its constituent gallic acid exhibit hypoglycemic effects, including stimulation of insulin secretion, inhibition of starch digestion, and reduction of protein glycation. Preclinical data from diabetic rodent models show reductions in plasma glucose and improved glucose tolerance. No robust human RCT focused solely on T. bellirica for glycemic control has been published, but the preclinical evidence is substantial.

Benfotiamine activates transketolase, shunting excess glucose metabolites into the pentose phosphate pathway and reducing formation of advanced glycation end products (AGEs). A small RCT in 13 type 2 diabetics showed it prevented micro- and macrovascular dysfunction triggered by an AGE-rich meal. The BOND trial (n=100, 12 months) found no significant change in HbA1c, suggesting the primary benefit is limiting glycation damage rather than directly lowering blood glucose.

Berberine is one of the most clinically studied botanical compounds for blood sugar regulation. Multiple meta-analyses of RCTs in type 2 diabetes patients show significant reductions in fasting plasma glucose, postprandial glucose, and HbA1c. It activates AMPK and has been compared favorably to metformin in some trials.

Carnosine (synthesized from BA) and BA itself have been associated with improved glycemic control in meta-analyses of human RCTs, with reductions in fasting blood glucose and HbA1c in people with prediabetes or type 2 diabetes. A 2025 meta-analysis (8 RCTs, n=377) reported significant reductions in fasting blood glucose (SMD: −0.53) and HbA1c (SMD: −0.36) vs. placebo. Most human effect is primarily attributed to carnosine supplementation, with limited direct BA-only human data.

Oat beta-glucan consistently reduces postprandial blood glucose and insulin excursions by slowing gastric emptying and carbohydrate absorption. A meta-analysis of RCTs in type 2 diabetic patients confirmed significant reductions in fasting plasma glucose and HbA1c. EFSA formally authorized a health claim for beta-glucan's reduction of post-meal glucose spikes.

Lower plasma betaine levels are associated with increased risk of type 2 diabetes and insulin resistance in epidemiological data. The Diabetes Prevention Program cohort found a 16% lower hazard for incident T2D per SD increase in plasma betaine. A 12-week RCT in obese prediabetic individuals showed betaine tended to reduce fasting glucose (p=0.08) and significantly reduced insulin area under the curve after oral glucose (p=0.038), though gold-standard insulin sensitivity by clamp was not improved.

Multiple animal studies demonstrate antihyperglycemic activity of Piper betle leaf extracts. Oral administration in streptozotocin-induced diabetic rats significantly reduced blood glucose and glycosylated hemoglobin. Mechanisms include modulation of hepatic gluconeogenic enzymes and alpha-glucosidase inhibition.

B. bifidum has been shown in animal models to reduce insulin resistance and improve lipid profiles in diabetic conditions, and synbiotic supplements including B. bifidum improved insulin metabolism and HDL-cholesterol in overweight T2DM patients with coronary heart disease in a human trial. Mechanisms include modulation of gut microbiota, FXR expression, and hepatic lipid regulation.

A crossover RCT of B. lactis TISTR 2591 in T2DM patients significantly attenuated fasting glucose elevation and improved HOMA-IR versus placebo. B. lactis HN019 in metabolic syndrome patients showed favorable trends in glucose metabolism. Evidence supports modest glycemic benefits as adjunctive therapy.

Clinical trials show select B. longum strains can modestly improve glycemic markers. A 12-week RCT found B. longum APC1472 significantly reduced fasting blood glucose in overweight/obese adults. A 2026 RCT of B. longum BL21 in type 2 diabetics on metformin showed a significant reduction in HbA1c. However, a meta-analysis of 6 RCTs found no overall significant effect of Bifidobacterium on fasting blood glucose.

Both bilberry fruit and leaf preparations have been studied for glycemic effects in human trials. A clinical study demonstrated that a standardized bilberry extract (36% anthocyanins) reduced postprandial glycemia and insulin in type 2 diabetes patients. A systematic review found bilberry and blackcurrant extract lowered HbA1c, particularly in older Chinese T2DM subjects in longer-term studies. Overall evidence is promising but not yet conclusive.

Bile acids regulate blood glucose through FXR-mediated suppression of hepatic gluconeogenesis and TGR5-mediated GLP-1 secretion from intestinal L-cells. Bile acid sequestrants have been demonstrated in human trials to improve glycemic control in type 2 diabetes and are FDA-approved for this indication (colesevelam). Bariatric surgery-associated rises in bile acids correlate with improved glycemia.

Multiple RCTs and meta-analyses confirm N. sativa significantly lowers fasting blood glucose and HbA1c in type 2 diabetic patients. A one-year placebo-controlled trial (n=114) showed significant reductions in FBG and HbA1c alongside improved antioxidant status. A meta-analysis of 34 studies confirmed significant glycaemic improvement.

Piperine inhibits intestinal alpha-glucosidases, potentially slowing post-meal glucose absorption, and may activate the CaMKKβ/AMPK pathway to promote GLUT4-mediated glucose uptake. Animal data are consistent, and some human RCTs using curcumin-piperine combinations document reductions in fasting blood glucose and HbA1c. Isolated piperine human trials are limited.

Human clinical evidence suggests black tea can influence postprandial glycemia partly by inhibiting intestinal glucose transport and modulating pancreatic beta-cell insulin secretion. Epidemiological studies associate regular tea consumption with a reduced risk of type 2 diabetes, though clinical trial results remain inconsistent.

Blackberry anthocyanins and fiber reduce postprandial glucose excursions and improve insulin sensitivity in preclinical models. Human and clinical literature on anthocyanins broadly (including blackberry-relevant C3G) demonstrates regulatory effects on fasting blood glucose and HbA1c in diabetic and prediabetic populations. Blackberries also have a low glycemic index and high fiber content that slows sugar absorption.

Multiple preclinical studies in streptozotocin-induced diabetic rats have shown that A. scholaris bark and leaf extracts significantly reduce fasting blood glucose, glycosylated hemoglobin, and lipid peroxidation. Alpha-glucosidase inhibitory activity has also been demonstrated in vitro. All supporting evidence is preclinical; no human clinical trials exist.

Multiple RCTs and meta-analyses show blueberry consumption can reduce fasting blood glucose and HbA1c, particularly in individuals with diabetes or prediabetes. Effects on insulin sensitivity are promising but inconsistent across trials. Anthocyanins appear to modulate glucose metabolism via gut-hormone and pancreatic pathways.

Lycium barbarum polysaccharides (LBPs) have demonstrated hypoglycemic effects in multiple animal and human studies. A randomized double-blind trial in T2DM patients showed LBP capsules (300 mg/day, 3 months) significantly reduced fasting and postprandial blood glucose while raising HDL and insulinogenic index. Meta-analysis confirms significant effects on fasting blood glucose regulation.

Multiple randomized controlled trials demonstrate that broccoli sprout extract (BSE), rich in sulforaphane, reduces fasting blood glucose and improves glycemic markers in type 2 diabetic patients. Sulforaphane inhibits hepatic gluconeogenesis via the Nrf2 pathway. A landmark Science Translational Medicine study confirmed improved fasting glucose in obese patients with dysregulated T2D.

Multiple RCTs and a 2021 PMC meta-analysis demonstrate that substituting brown rice for white rice significantly reduces postprandial blood glucose and, in some trials, HbA1c. A Nature Nutrition & Diabetes RCT in Japanese diabetic patients showed HbA1c fell from 7.5% to 7.2% after 8 weeks of glutinous brown rice. Brown rice protein, as a concentrated extract of whole brown rice, retains bioactive compounds including dietary fiber, resistant starch, phenolics, and γ-oryzanol that contribute to these effects.

Brussels sprouts have a low glycemic index and contain soluble fiber that slows postprandial glucose absorption. Alpha-lipoic acid (ALA) in Brussels sprouts has been studied for effects on glucose metabolism. Cruciferous vegetable class RCT evidence shows improved glycaemic control versus control vegetables.

Preclinical (animal and in vitro) research suggests buchu aqueous extract may normalize blood glucose and enhance cellular glucose uptake. A 2025 computational study identified buchu essential oil compounds as candidate PTP1B inhibitors relevant to insulin signaling. No human clinical trials exist; all positive findings remain at the preclinical stage.

Burdock root contains arctigenin, fructooligosaccharides, and chlorogenic acid, which have shown antidiabetic properties in animal and in vitro studies. A 2022 review confirmed these effects in preclinical models, noting improvement in blood glucose, glucose tolerance, and insulin sensitivity. Human RCT data remain limited but preliminary findings suggest modest glucose-lowering effects.

Butyrate plays a significant role in glucose homeostasis and energy metabolism, with supporting evidence from human clinical studies. A Frontiers in Nutrition semi-systematic review (2025) identified multiple clinical trials reporting effects of elevated butyrate production on glucose and insulin markers. An RCT of sodium butyrate in obesity found reductions in blood sugar alongside weight and BMI. Tributyrin's effect on glucose in humans is inferred primarily from animal data and sodium butyrate human trials.

Multiple human trials indicate that butyrate supplementation can improve fasting glucose, HbA1c, and reduce postprandial glucose excursions. Effects appear more consistent in lean individuals than in those with metabolic syndrome, and mechanisms involve delayed gastric emptying and GLP-1 stimulation.

Cabbage is low in digestible carbohydrates, high in fiber, and contains anthocyanins and sulforaphane—compounds associated with improved glycemic control. Its low glycemic index means it does not cause sharp blood sugar spikes. Epidemiological and animal data support a role in blood sugar regulation, with emerging human evidence from cruciferous vegetable intervention studies.

A 2021 review in the Journal of Food Science (Wiley) summarized scientific evidence that cabbage (Brassica oleracea var. capitata) has multi-target effects on glucose homeostasis due to high bioactive compound content. Glucosinolate-derived isothiocyanates and flavonoids in cabbage have demonstrated alpha-glucosidase inhibitory activity, reducing postprandial glucose spikes. Animal and preliminary human data support hypoglycemic effects relevant to type 2 diabetes management.

Multiple preclinical studies and at least one small human pilot study support antidiabetic and hypoglycemic activity for C. crista seed extracts. Aqueous and ethanolic seed extracts reduced blood glucose in streptozotocin and alloxan-induced diabetic animal models. A small human study in male diabetic patients using 500–1000 mg/day showed modest reductions in fasting and random blood glucose over two months.

Plasma campesterol levels are altered in type 2 diabetes, where they are significantly lower than in healthy controls, reflecting metabolic disruption of cholesterol absorption. Campesterol:cholesterol ratio is negatively associated with insulin levels in metabolic syndrome subjects. Campesterol is not itself a direct glycemic agent but is implicated as a metabolic marker of insulin-related cholesterol dysregulation.

A small human study (n=23) found that camu camu juice attenuated postprandial blood glucose spikes. Animal studies in obese/diabetic mice show that camu camu extract improved glucose homeostasis and reduced HbA1c-related markers. A human crossover RCT in overweight hypertriglyceridemic adults also measured glycated hemoglobin and indices of glucose homeostasis as secondary outcomes.

Clinical and preclinical evidence indicates capsaicinoids can reduce postprandial blood glucose and stimulate insulin secretion via TRPV1-dependent mechanisms. Human studies including an RCT published in Am J Clin Nutr show modulation of postprandial glucose. Larger-scale human trials are still needed to confirm clinical significance.

Capsanthin has demonstrated antidiabetic and glucose-normalizing effects in rodent models, including significant reversal of glucose intolerance in high-fat-diet mice. AMPK activation and adiponectin upregulation are proposed mechanisms. No human clinical trials have yet confirmed these effects.

Capsaicin has demonstrated glycemic-modulating effects through TRPV1 receptor activation, which can decrease inflammation, raise adiponectin, and improve insulin sensitivity. Human evidence from RCTs in metabolic syndrome populations supports modest effects on fasting glucose, though results are not fully consistent across trials.

Several RCTs and a systematic review have examined cardamom's effects on glycemic parameters in type 2 diabetes and prediabetes populations. Results show improvement in insulin resistance (HOMA-IR), serum SIRT1 upregulation, and modest improvements in fasting blood glucose in some trials. A 2024 comprehensive systematic review confirmed beneficial effects on antioxidant enzyme activity and oxidative stress in diabetes, though glycemic effects are not uniformly significant across all trials.

Carrot dietary fiber, particularly the insoluble fiber fraction, slows glucose absorption and blunts postprandial glycemic response. Bioactive compounds in black carrot demonstrate antidiabetic properties in vitro and in animal models. Limited human clinical evidence exists for carrot fiber's glycemic effects.

Preclinical evidence consistently shows BCP improves glycemic parameters in diabetic animal models by activating CB2 and PPAR-γ receptors. It has been shown to protect pancreatic beta-cells, improve insulin signaling, and reduce hyperglycemia-related damage. No human clinical trials have been published to date.

Multiple randomized clinical trials and a 2021 systematic review and meta-analysis demonstrate that cassia bark (1–6 g/day) can produce meaningful reductions in fasting blood glucose in people with type 2 diabetes. Results are mixed, with some trials showing no effect, and HbA1c reductions have been inconsistent. The body of evidence is the strongest for any single health claim associated with cassia bark.

CAT gene mutations and reduced catalase activity are associated with diabetes mellitus and insulin resistance. Catalase glycation—the non-enzymatic modification of the enzyme in hyperglycemic conditions—impairs its function, worsening β-cell oxidative stress. Acatalasemia (inherited catalase deficiency) is associated with an increased risk of type 2 diabetes.

Green tea catechins significantly lower fasting blood glucose in multiple RCTs and meta-analyses. A 22-RCT meta-analysis (n=1,584) found catechins reduced fasting blood glucose by −1.48 mg/dL, with the effect most apparent at ≥12 weeks. Effects on HbA1c and fasting insulin are less consistent.

Cowpea (Vigna unguiculata, of which catjang is a subspecies) has demonstrated low glycemic index values in human trials and shows enzymatic inhibition of carbohydrate-digesting enzymes in vitro. Bioactive peptides have been shown to activate insulin-like signaling pathways. These effects are attributed to its high dietary fiber content and polyphenol-rich profile.

Cauliflower is very low in digestible carbohydrates, and its fiber slows carbohydrate absorption. Sulforaphane activates AMPK and Nrf2 pathways to reduce oxidative-stress-driven glycemic dysregulation. Human RCTs using SFN-rich crucifer extracts show significant reductions in fasting glucose and HbA1c.

Human evidence for capsaicin's effect on blood glucose is mixed. An OGTT study in 12 healthy volunteers showed capsaicin increased plasma insulin and attenuated blood glucose. However, a meta-analysis of 14 human trials found no significant effect on fasting blood glucose versus placebo. Animal studies consistently show benefit but human data are limited and conflicting.

A 2025 meta-analysis of 10 RCTs (511 participants) found celery preparations significantly reduced fasting plasma glucose (SMD: −0.80). NBP and other celery phytochemicals are proposed to improve insulin sensitivity. A randomized trial in prediabetic patients also showed glucose-lowering effects.

Multiple preclinical studies demonstrate that A. aspera seed and leaf extracts reduce blood glucose in streptozotocin- and alloxan-induced diabetic animal models. In vitro work shows inhibition of key glycemic enzymes (α-amylase, α-glucosidase, DPP-4). No human clinical trials have yet been published.

Multiple RCTs have found chamomile tea consumption significantly reduces fasting blood glucose, HbA1c, serum insulin, and HOMA-IR in type 2 diabetic patients. A 2024 meta-analysis of 4 human clinical trials confirmed favorable pooled effects on fasting blood glucose and HbA1c. Polyphenols in chamomile appear to inhibit carbohydrate-digesting enzymes and reduce postprandial glucose absorption.

Chen Pi flavonoids—hesperidin and PMFs—inhibit α-glucosidase activity, improve insulin sensitivity, and reduce fasting blood glucose in human trials. A 2023 meta-analysis of RCTs with hesperidin found a significant reduction in fasting blood glucose and improved insulin sensitivity index.

The mucilaginous fiber in chia seeds slows carbohydrate digestion and reduces postprandial glucose spikes by 22–30% in controlled meal studies. A systematic review and meta-regression of 14 RCTs confirmed modest improvements in glycemic markers. Effects on fasting glucose and HbA1c are real but small.

A 2025 systematic review and meta-analysis of 28 controlled trials found chickpea consumption significantly reduced postprandial glucose incremental AUC versus carbohydrate-matched controls (MD: −47.89, p<0.0001). The protein and resistant starch in chickpeas inhibit α-glucosidase and slow intestinal glucose absorption. Evidence certainty is low to very low due to heterogeneity across studies.

Chicory inulin and oligofructose are not digested in the upper GI tract, leading to a substantially lower postprandial blood glucose response compared to sugars. Replacing at least 30% of sugars with chicory root fiber carries an EU-authorized health claim for lowering postprandial blood glucose. A 2021 systematic review of 23 studies found improved glycemic indices in 15 of 19 evaluating studies.

Randomized clinical trials and meta-analyses indicate chlorella supplementation significantly reduces fasting blood glucose and HOMA-IR (insulin resistance index). A 2018 meta-analysis of 19 RCTs and a 2025 GRADE-assessed systematic review both reported significant reductions in fasting blood glucose.

Chlorophyll-containing thylakoids and chlorophyll derivatives have demonstrated blood glucose-modulating effects in human and animal studies. Thylakoid supplementation with carbohydrate-rich meals reduced postprandial blood glucose and prevented hypoglycemic rebound in human and pig studies. Chlorophyll derivatives including pheophorbide a and pyropheophytin a may inhibit α-glucosidase and α-amylase, slowing carbohydrate digestion.

Human clinical evidence for chokeberry's glycaemic effects is mixed. Some clinical trials in metabolic syndrome patients and those with carbohydrate metabolism disorders show reductions in fasting blood glucose, but a 2026 systematic review and meta-analysis of 7 RCTs found no significant overall effect on fasting blood sugar. In vitro and animal data support mechanisms including α-glucosidase inhibition.

Chromic chloride (trivalent chromium) has been studied in multiple clinical trials for glycemic control. Meta-analyses show inconsistent but sometimes significant reductions in fasting glucose and HbA1c, primarily in people with type 2 diabetes. Effects in healthy individuals are minimal. Chromium chloride specifically showed a non-significant effect on fasting glucose in subgroup analyses compared to other forms.

Chromium is a trace mineral required for the formation of glucose tolerance factor (GTF), which potentiates insulin action. A 2020 meta-analysis of 28 studies showed chromium supplementation significantly reduced fasting plasma glucose, insulin, HbA1c, and HOMA-IR in diabetic patients. A 2022 meta-analysis found significant HbA1c reduction.

Early clinical and preclinical evidence suggests chrysanthemum extracts may lower blood glucose through insulin-sensitizing mechanisms. A small human study of a chrysanthemum-chromium combination (jiangtangkang) reported reductions in type 2 diabetic patients over 6 months. Preclinical data show hypoglycemic and anti-obesity properties attributed to polysaccharides and flavonoids.

Multiple preclinical studies demonstrate that chrysin reduces fasting blood glucose and improves glucose tolerance in diabetic animal models. A nanoparticle formulation (chrysin-loaded phytosome) significantly improved insulin resistance and OGTT outcomes in db/db mice, while plain chrysin alone did not achieve the same effect. Mechanisms include GLUT4 upregulation, AMPK/PI3K/AKT pathway activation, and suppression of gluconeogenesis. No human clinical trials have been published.

Cinnamon (primarily Cinnamomum cassia) has been studied in multiple clinical trials for its ability to improve fasting blood glucose in patients with T2DM and prediabetes. Active compounds including cinnamaldehyde enhance insulin receptor signaling and GLUT-4 translocation. Several meta-analyses confirm modest but significant FBG-lowering effects.

Multiple randomized controlled trials in overweight and obese participants have shown significant reductions in fasting blood glucose following 8–10 weeks of Cissus quadrangularis extract (CQR-300, 300 mg/day). The mechanism is partly attributed to inhibition of pancreatic lipase and amylase, and modulation of insulin sensitivity. These findings are consistent across several human trials, though studies are primarily from one research group.

Citrus pectin, as a viscous soluble fiber, attenuates postprandial blood glucose responses by slowing gastric emptying and intestinal glucose absorption. Human clinical trials and a systematic scoping review including 47 human studies confirm glycemic benefits. Orange pomace fiber (rich in citrus pectin) significantly reduced postprandial glucose in a crossover clinical trial.

Hesperidin from C. sinensis significantly reduces fasting blood glucose in RCTs, including a meta-analysis of 12 trials. A 6-month RCT in prediabetic subjects showed normalization of glucose from impaired fasting range to normal in the treatment group. Preclinical data suggests GLUT4 upregulation and PPAR-γ activation as mechanisms.

CLA's effects on blood glucose are mixed and isomer-dependent. Some RCTs show improvement in HbA1c and insulin resistance in specific populations (e.g., NAFLD, obese children), while other meta-analyses find CLA may modestly raise fasting blood glucose. Effects appear highly context-dependent.

A human pilot study demonstrated that 250 mg/day of polyphenol-rich clove extract lowered pre- and post-prandial blood glucose in healthy and pre-diabetic volunteers. Preclinical data show eugenol inhibits α-amylase and α-glucosidase and improves insulin secretion from pancreatic islets.

Cocoa flavanols have demonstrated significant reductions in fasting blood glucose in meta-analyses of RCTs. A 2024 meta-analysis of 31 RCTs found fasting blood glucose reduced by −4.91 mg/dL. Effects on HbA1c are inconsistent. Evidence is stronger in populations with dysglycemia.

Multiple meta-analyses of RCTs find that coconut oil's acute effect raises postprandial glucose while decreasing insulin response. Long-term glycemic markers are not significantly altered compared to other cooking oils in most analyses, though one systematic review suggests coconut oil may increase insulin resistance. Evidence is mixed and overall quality is low to moderate.

The fat content of coconut milk—primarily MCTs—slows gastric emptying and delays starch digestion via amylose-lipid complex formation, blunting postprandial blood glucose responses. Animal and limited human data support a modest glycemic-moderating effect, though direct clinical trials in humans with coconut milk specifically are limited.

Chlorogenic acid, the primary bioactive in coffee fruit, inhibits glucose-6-phosphatase and modulates glucose absorption, reducing postprandial glucose. A meta-analysis of six RCTs found green coffee extract (sharing coffee fruit's key CGAs) significantly reduced fasting blood glucose (SMD −0.32). An RCT in metabolic syndrome patients found coffee extract significantly attenuated fasting blood sugar versus placebo.

Multiple preclinical studies and a small number of human trials suggest coix seed and its extracts (polysaccharides, prolamin hydrolysates, seed oil) can lower fasting blood glucose, improve glucose tolerance, and inhibit carbohydrate-digesting enzymes. Evidence in humans is preliminary but exists.

A randomized controlled trial found that Coleus forskohlii extract significantly improved insulin concentration and insulin resistance in overweight subjects on a hypocaloric diet. Preclinical research shows forskolin enhances glucose-stimulated insulin release from pancreatic beta cells via cAMP elevation. Human evidence is limited to small trials but directionally consistent.

Collard greens have a very low glycemic index (~15) and provide approximately 7–8 grams of fiber per cooked cup, slowing glucose absorption. The fiber content has been linked to reduced inflammation and improved glycemic control in both type 1 and type 2 diabetes in published studies. The antioxidant alpha-lipoic acid in collards may further improve insulin sensitivity.

Berberine from Coptis chinensis has robust clinical evidence for lowering blood glucose in type 2 diabetes, comparable to metformin in some trials. Multiple RCTs and meta-analyses confirm reductions in HbA1c, fasting glucose, and postprandial glucose. Mechanisms include AMPK activation, inhibition of hepatic gluconeogenesis, and improved insulin sensitivity.

Multiple RCTs and meta-analyses show CoQ10 supplementation modestly reduces fasting blood glucose and HbA1c, particularly in patients with type 2 diabetes. A 2022 GRADE-assessed meta-analysis of 40 RCTs concluded that 100–200 mg/day provides the greatest glycemic benefit. Results remain somewhat heterogeneous across trials. The primary mechanism is reduction of mitochondrial oxidative stress in pancreatic beta cells and peripheral tissues.

Multiple preclinical studies demonstrate that Cordyceps extracts and cordycepin lower fasting blood glucose, increase hepatic glycogen, and improve oral glucose tolerance in diabetic animal models. The active compound cordycepin in C. militaris produced a 47% reduction in blood glucose in alloxan-induced diabetic mice. Proposed mechanisms include cholinergic activation of insulin secretion and upregulation of GLUT-4 and IRS-1. Human RCT evidence is limited; a trial combining Ganoderma with Cordyceps in T2DM patients showed no significant effect on HbA1c.

Both corn silk extracts and soluble corn fiber (SCF) have human and clinical evidence supporting blood glucose modulation. Corn silk flavonoids significantly reduced blood glucose in diabetic animal models, and SCF demonstrated reduced postprandial glycemic response in human RCTs. Mechanisms include alpha-glucosidase inhibition and enhanced insulin sensitivity.

Multiple preclinical studies demonstrate that corn silk extracts lower blood glucose and HbA1c in diabetic animal models, partly by stimulating insulin secretion and supporting pancreatic beta-cell recovery. Active constituents include polysaccharides, flavonoids, and phenolic acids that inhibit alpha-glucosidase and advanced glycation end-product (AGE) formation. Human clinical evidence remains limited, though the mechanistic data is robust at the preclinical level.

Corosolic acid is the primary bioactive triterpenoid of banaba leaf (Lagerstroemia speciosa) and has demonstrated blood glucose-lowering effects in human subjects. A clinical trial found that corosolic acid reduced blood glucose levels within 60 minutes. Multiple human studies confirm a 12–30% reduction in fasting blood glucose.

The 8-week RCT in hypercholesterolemic adults showed CSO diet enrichment improved postprandial glycemia compared to olive oil, specifically attenuating the plasma glucose rise following a high-saturated-fat challenge meal. This was a secondary outcome in the trial; no dedicated CSO blood sugar trials exist.

Multiple RCTs and meta-analyses show cranberry consumption can reduce fasting blood glucose, HbA1c, and insulin resistance, with significant effects observed primarily in individuals with type 2 diabetes. A 2022 meta-analysis found meaningful reductions in fasting glucose (MD: −17.72 mg/dL) and HbA1c in diabetic subjects. Effects in non-diabetic populations are less consistent. Cranberry polyphenols are thought to inhibit carbohydrate digestion and modulate insulin signaling.

Clinical evidence suggests creatine supplementation, particularly combined with exercise, may improve glucose regulation through enhanced GLUT-4 transporter activity. Proposed mechanisms include increased beta-cell insulin secretion and improved muscle glycogen storage. A 2021 systematic review and meta-analysis found null effects on fasting glucose overall, though individual trials in diabetic populations showed benefit.

Creatine monohydrate, primarily when combined with exercise, has been shown in human clinical trials to improve glycemic control in people with type 2 diabetes. The principal mechanism involves enhanced GLUT-4 translocation increasing muscle glucose uptake. Evidence in sedentary or healthy populations without exercise is weak.

Multiple animal studies demonstrate cucumber extract lowers fasting blood glucose in diabetic models, and at least one small human RCT in women with type 2 diabetes found cucumber juice reduced fasting blood glucose and HbA1c. The mechanism involves inhibition of α-glucosidase and α-amylase, and protective effects on pancreatic beta cells. Human clinical evidence remains limited but exists.

Multiple RCTs in diabetic patients show cumin supplementation can reduce fasting blood glucose and HbA1c. A 2021 meta-analysis (8 RCTs, 552 participants) found a trend toward FBS reduction, though not reaching conventional significance (p=0.06). A 2025 GRADE-assessed meta-analysis (9 RCTs) found a significant FBS reduction (SMD: −1.38; p=0.002), particularly in adults over 50. Evidence is promising but inconsistent across trials.

Curcumin, the primary bioactive compound in turmeric, has been evaluated in multiple RCTs for T2DM. It reduces fasting blood glucose and HbA1c, improves insulin sensitivity, and has anti-inflammatory effects relevant to metabolic disease. A systematic review and meta-analysis confirms significant glycemic benefits.

Curcuminoids are the collective group of bioactive phenolic compounds in turmeric (Curcuma longa), with curcumin as the primary constituent. RCTs and meta-analyses confirm that curcuminoid supplementation reduces fasting blood glucose, HbA1c, and HOMA-IR in T2DM patients through anti-inflammatory and AMPK-activating mechanisms.

Blackcurrant polyphenols have shown postprandial blood glucose-lowering effects in human crossover trials. The fiber content also slows sugar absorption. Animal model data further support improved glucose regulation and insulin expression with blackcurrant juice. Evidence in humans remains preliminary.

Alpha-tocopherol has been investigated in diabetes and insulin resistance as an antioxidant that may protect against oxidative stress–driven pancreatic beta-cell damage and insulin resistance. Evidence includes StatPearls noting wound healing benefits in diabetes and NAFLD trial data where α-tocopherol reduced metabolic dysfunction associated with insulin resistance.

D-Pinitol (3-O-methyl-D-chiro-inositol) is a naturally occurring inositol derivative found in plants including legumes and soy. Clinical studies show it improves insulin-mediated glucose uptake and lowers blood glucose in T2DM patients and insulin-resistant individuals. It acts as an insulin sensitizer via inositol phosphoglycan mediator pathways.

Daidzin has shown blood glucose-lowering effects in streptozotocin-induced diabetic mice, primarily through glucosidase inhibition, stimulation of glucose consumption, and GLUT4 upregulation. A mixture of daidzin and glycitin also reduced blood glucose and HbA1c in high-fat diet mice. Evidence remains preclinical.

Multiple preclinical studies support damiana's hypoglycemic activity. Bioassay-guided isolation identified teuhetenone A as the primary active compound responsible for blood glucose reduction in diabetic mouse models. A 2025 in-vitro study additionally showed improved glucose uptake in myocytes. All evidence is preclinical; no human clinical trials exist.

Dandelion contains bioactive compounds including chicoric acid, chlorogenic acid, and inulin that may modulate glucose metabolism. A small randomized clinical trial in type 2 diabetic patients found significant reductions in fasting blood glucose with dandelion leaf and root powder versus placebo. Preclinical evidence is more extensive, but human data remain limited.

Devil's Claw has been shown in animal models to lower blood glucose levels, and clinical pharmacology sources caution diabetic patients that it may lower blood sugar when combined with hypoglycemic medications. The 2019 NCCIH digest includes a specific caution about this effect. The mechanism is not fully elucidated.

Multiple preclinical studies and a systematic review demonstrate that Dioscorea extracts and key constituents (dioscorin, dioscin, diosgenin, allantoin, polysaccharides) reduce fasting blood glucose and improve glucose tolerance in rodent models of diabetes. A 2022 systematic review in the British Journal of Nutrition found all ten included animal studies showed glycaemic improvement. Human clinical evidence remains limited and more trials are needed.

Multiple preclinical studies demonstrate that Cuscuta reflexa and C. chinensis extracts reduce blood glucose levels, improve insulin sensitivity, and protect against diabetic complications in animal models. The antidiabetic effects are attributed to flavonoids, polysaccharides, and phenolic acids that modulate glucose metabolism. Human clinical evidence remains limited, but the preclinical data are substantial.

Several clinical trials and a systematic review have evaluated Rosa canina for blood glucose and HbA1c outcomes. One RCT (Dabaghian et al., 2015) examined aqueous rosehip extract in type-2 diabetic patients. A systematic review (2023) of 4 RCTs reported reductions in fasting blood glucose and HbA1c as secondary findings in some trials, though results are inconsistent across dosages.

Cornus officinalis (Asian dogwood) has been extensively studied for hypoglycemic effects. Preclinical studies show α-glucosidase inhibition, improved insulin resistance, and reduced fasting blood glucose in diabetic animal models. Limited human clinical data exist, but the evidence base is the strongest of any dogwood species for this indication.

Dulse protein hydrolysates inhibit DPP-IV enzyme activity in vitro, a mechanism used by a class of antidiabetic drugs to prolong insulin action. Dulse-derived peptides also stimulated insulin and incretin (GLP-1, GIP) secretion in cell models, and a crude hydrolysate improved glycaemia in streptozotocin-induced diabetic mice. Dulse xylan-derived xylooligosaccharides further inhibited α-glucosidase and α-amylase, relevant to controlling postprandial blood glucose.

EGCG is the predominant catechin in green tea and has been studied for its effects on insulin sensitivity and blood glucose. Meta-analyses of clinical trials show green tea/EGCG supplementation significantly reduces fasting blood glucose. It enhances insulin signaling, inhibits alpha-glucosidase, and reduces hepatic glucose output.

Clinical trials in people with pre-diabetes and type 2 diabetes indicate that regular egg consumption does not adversely affect glycemic control and may modestly improve fasting blood glucose and insulin sensitivity. High-egg diets have not worsened cardiometabolic markers in diabetic populations over periods up to 12 months.

Elecampane root contains up to 44% inulin, a prebiotic fructan with documented hypoglycemic properties in clinical studies. In vitro and animal data also suggest hypoglycemic activity from other constituents. Clinical evidence for inulin as a glucose-modulating prebiotic is well-supported, though trials using elecampane itself are absent.

Clinical and preclinical evidence suggests eleuthero may improve glucose metabolism and insulin sensitivity. One human study found 480 mg/day of extract reduced fasting and postprandial blood glucose and HbA1c. Animal studies identify eleutheroside E as a key driver of improved pancreatic function and reduced insulin resistance.

Multiple clinical and preclinical studies confirm E. littorale lowers fasting and postprandial blood glucose in type 2 diabetic patients and animal models. A published clinical trial in 84 T2D patients showed significant reductions in blood glucose and serum insulin after three months. The key mechanism involves insulinotropic activity at pancreatic islets via a K⁺-ATP channel-dependent pathway.

Eucommia leaf extract shows antidiabetic activity across several animal models, improving glucose tolerance, reducing blood glucose, and enhancing insulin sensitivity. Active compounds including chlorogenic acid and quercetin glycoside improve glucose uptake and glycogen production. Human trial data are lacking.

Several small clinical trials indicate EPO may modestly improve insulin sensitivity and fasting glucose, particularly in diabetic or pre-diabetic populations. A triple-blind RCT in pre-diabetic postmenopausal women and a study combining EPO with vitamin D in gestational diabetes both showed improvements in glucose and insulin resistance markers. Evidence remains preliminary due to small sample sizes.

Fava beans have a low-to-moderate glycemic index (~25–40 depending on preparation) and a very low glycemic load per serving. Their soluble fiber and resistant starch slow glucose absorption and attenuate postprandial glycemia, supported by clinical and preclinical studies. A legume-rich low-GI diet RCT showed significantly greater HbA1c reductions vs. high-wheat-fiber diet in type 2 diabetics.

Preclinical studies demonstrate that fennel essential oil and seed extracts reduce blood glucose in diabetic animal models, with antioxidant co-benefits. Human evidence specific to fennel (Foeniculum vulgare) on glycemia is limited to animal and in vitro data; human trials showing hypoglycemic effects mainly involve fenugreek (Trigonella foenum-graecum), a distinct plant. Fennel's low glycemic load supports its use as a dietary food for blood sugar management.

Fenugreek seeds have a long history of use as a traditional diabetes remedy across Asia and the Middle East. Clinical trial meta-analyses show fenugreek can reduce fasting and postprandial blood glucose in T2DM and prediabetes patients. Mechanisms include inhibition of carbohydrate-digesting enzymes, enhanced GLUT4 translocation, and insulinotropic effects.

Multiple animal studies demonstrate that Ferula asafoetida oleo-gum-resin extract significantly lowers blood glucose in streptozotocin-induced diabetic rats. Antidiabetic activity is attributed to ferulic acid and tannins. A PCOS clinical trial also measured fasting blood sugar as a secondary outcome. Human clinical evidence is limited.

Ferulic acid inhibits α-glucosidase and α-amylase (enzymes governing postprandial glucose rise), stimulates insulin secretion from pancreatic β-cells, and improves insulin sensitivity via PI3K/Akt signaling. Multiple animal studies demonstrate reduced fasting glucose and improved glucose tolerance. In vitro work with human erythrocytes shows FA reduces glycated hemoglobin (HbA1c) under high-glucose conditions. Direct human glucose RCTs remain limited.

Multiple preclinical studies demonstrate fisetin reduces fasting blood glucose, insulin resistance (HOMA-IR), and HbA1c in diabetic rodent models. It improves glucose metabolism via AMPK and SIRT1 pathway activation. No dedicated human RCTs exist, though early-phase clinical trials for related metabolic endpoints are registered.

Fish oil primarily lowers serum triglycerides in people with type 2 diabetes, with modest or inconsistent direct effects on fasting blood glucose or HbA1c. A meta-analysis of 45 RCTs in >2,600 T2DM patients found omega-3 supplementation associated with significant reductions in triglycerides and HbA1c. Fish oil may improve insulin sensitivity partly through anti-inflammatory mechanisms acting on PPAR-γ expression.

Multiple RCTs and meta-analyses support flaxseed's ability to reduce fasting blood glucose, postprandial glycemia, insulin, and HOMA-IR, particularly in individuals with type 2 diabetes or prediabetes. A meta-analysis of 25 RCTs found significant reductions in blood glucose and insulin resistance. Effects are stronger with whole or ground flaxseed versus oil.

Related Chaenomeles species (C. sinensis) have been studied in rodent models of diabetes, showing antihyperglycemic and antihyperlipidemic effects. C. speciosa itself is noted to have alpha-glucosidase and alpha-amylase inhibitory activity in vitro, relevant to postprandial glucose modulation. Evidence is entirely preclinical.

Forskolin raises cAMP in pancreatic beta cells, enhancing glucose-stimulated insulin release and improving insulin sensitivity markers in human studies. A 12-week RCT in overweight/obese subjects showed significant improvement in insulin concentration and insulin resistance compared to placebo.

Inulin-type fructans including FOS have demonstrated significant reductions in fasting blood glucose in people with prediabetes and type 2 diabetes across multiple RCTs, though effects are less consistent in healthy individuals. A 2021 meta-analysis of 33 RCTs found significant blood glucose lowering only in diabetic subjects. FOS itself showed no independent glycemic benefit in a 2025 RCT comparing FOS vs. inulin in overweight/obese adults. Evidence in healthy populations remains mixed.

A 2022 PLOS ONE systematic review of 73 RCTs (6,489 participants) found that Fuling herbal formulae added to hypoglycaemic agents significantly reduced fasting blood glucose, 2-hour postprandial glucose, and HbA1c in type 2 diabetes. Triterpenes from P. cocos also showed anti-hyperglycaemic effects in animal models via PPAR-γ activation. Evidence is rated low-to-moderate due to risk of bias.

FvA has been identified as a candidate for modulating blood glucose through immune and oxidative stress pathways that are hallmarks of diabetes. Traditional use for diabetes is documented. A 2018 peer-reviewed minireview found substantial preclinical evidence supporting FvA research in chronic inflammatory diseases including diabetes.

A 2025 systematic review of preclinical studies found gamma oryzanol exerts beneficial effects on glycaemic control by enhancing insulin secretion and sensitivity and reducing fasting blood glucose. A human clinical observation noted modest improvements in FBG and HbA1c. Preclinical mechanisms include AMPK activation and GLUT4 translocation.

Multiple human RCTs and a 2025 meta-analysis of 17 RCTs (n=971) have examined Ganoderma's effects on blood glucose. Results are mixed: some smaller trials report reductions in HbA1c and fasting glucose in type 2 diabetes patients, while a well-designed 16-week RCT found no significant effect. Preclinical evidence for AMPK-mediated insulin sensitisation is robust.

Multiple controlled trials and a 2025 systematic review and meta-analysis (28 studies, 40 comparisons) confirm that chickpea consumption significantly reduces postprandial glucose incremental AUC versus carbohydrate-matched controls (MD: −47.89, 95% CI: −64.20 to −31.58, p<0.0001). No significant effect on peak glucose or insulin AUC was observed. Evidence certainty is rated low to very low by GRADE.

Geniposide and genipin from Gardenia jasminoides have well-documented hypoglycemic activity in multiple animal models of type 2 diabetes. Geniposide inhibits hepatic glucose-6-phosphatase and glycogen phosphorylase to reduce glucose output, and genipin inhibits UCP2 to restore pancreatic beta-cell insulin secretion. Human use in China for diabetes management has historical grounding in the Chinese Pharmacopoeia.

Multiple preclinical studies demonstrate that Gardenia jasminoides and its active components geniposide and crocin I exert hypoglycemic effects in type 2 diabetic animal models. Mechanisms include UCP2 inhibition by genipin (stimulating pancreatic beta-cell insulin secretion), GLP-1 receptor agonism by geniposide, and reduced oxidative stress in islet cells. No human clinical trials have confirmed these effects.

Multiple meta-analyses of RCTs confirm garlic supplementation significantly lowers fasting blood glucose (FBG) and HbA1c in type 2 diabetic patients. A 2024 meta-analysis found garlic intervention significantly reduced FBG (mean difference −7.01 mg/dL) and HbA1c (−0.66%). Evidence is strongest when garlic is used adjunctively with standard antidiabetic medications.

Multiple RCTs and meta-analyses show garlic supplementation significantly reduces fasting blood glucose and HbA1c in type 2 diabetic patients. The proposed mechanism involves enhanced insulin secretion from pancreatic beta-cells, improved insulin sensitivity, and allicin-mediated reduction of insulin resistance. Effects are most pronounced in diabetic, not healthy, populations.

Multiple RCTs and meta-analyses show genistein significantly reduces fasting blood glucose and HbA1c, particularly in postmenopausal women with type 2 diabetes. A 2017 meta-analysis of 7 RCTs found genistein reduced fasting glucose by approximately 6.35 mg/dL versus placebo. Preclinical evidence shows genistein supports pancreatic beta-cell function and glucose-stimulated insulin secretion.

Gentiana species contain bitter iridoid glycosides that interact with intestinal bitter taste receptors on enteroendocrine L-cells, stimulating GLP-1 secretion and thereby influencing glucose homeostasis. A cell-line study using Gentiana scabra demonstrated GLP-1 secretion from human NCI-H716 enteroendocrine cells via a GPCR pathway. The key compound gentiopicroside (GPS) has also been identified in review literature as having antidiabetic properties via NF-κB and MAPK pathway modulation. Most evidence remains preclinical; no large human RCTs isolating gentian root on blood glucose exist.

Geranium EO has demonstrated significant hypoglycemic activity in alloxan-induced diabetic rat models, outperforming the reference drug glibenclamide at 150 mg/kg. In vitro studies confirm α-glucosidase and α-amylase inhibition. Human clinical evidence is not yet available.

Multiple RCTs and meta-analyses support ginger's ability to reduce fasting blood glucose and HbA1c in type 2 diabetic patients. A meta-analysis of 10 RCTs (490 individuals) found a pooled weighted mean difference in HbA1c of −1.00 (95% CI: −1.56, −0.44; P<0.001). Results in non-diabetic populations are more modest.

Ginseng extracts (particularly American ginseng, Panax quinquefolius, and Asian ginseng, Panax ginseng) have been clinically studied for blood sugar regulation. Multiple trials support anti-hyperglycemic, insulin-sensitizing, and islet-protective effects. Endotext (NCBI) lists American ginseng as having the best RCT evidence among natural products for blood glucose lowering.

Ginsenosides are the primary bioactive saponins in Panax ginseng and Panax quinquefolius, responsible for the anti-hyperglycemic and insulin-sensitizing effects of ginseng. They have been shown in multiple model systems and some clinical trials to reduce blood glucose, improve insulin sensitivity, and protect pancreatic islet cells.

GLA's primary connection to blood sugar is through diabetic neuropathy: diabetics have an impaired ability to convert linoleic acid to GLA, and GLA supplementation corrects the downstream deficit in nerve membrane lipids. GLA itself does not directly lower blood glucose but addresses glucose-related nerve damage and metabolic dysregulation downstream of glycemic disruption.

Glucoamylase is the rate-limiting enzyme in the conversion of dietary starch oligomers to free glucose at the intestinal brush border, making it a direct determinant of the pace and magnitude of postprandial blood glucose rise. Animal studies confirm that loss of this enzymatic step significantly elevates postprandial glycemia.

Multiple RCTs and meta-analyses demonstrate that glucomannan significantly lowers fasting blood glucose and postprandial glucose. A 2023 PMC meta-analysis of 6 RCTs (n=440 T2DM patients) found significant reductions in FBG (MD −1.08 mmol/L), 2-hour postprandial glucose, and fasting insulin. The primary mechanism is the formation of a highly viscous gel in the GI tract that slows gastric emptying and carbohydrate absorption.

Plasma glycine is consistently low in obesity and type 2 diabetes, and prospective studies show hypoglycinemia predicts incident T2D. A clinical trial found 5 g glycine before an oral glucose tolerance test improved glucose tolerance in healthy subjects and first-degree relatives of T2D patients. Glycine appears to stimulate glucose-dependent GLP-1 secretion and insulin release.

Hypoglycemic effects are directly attributed to glycitin/glycitein in systematic reviews. Soy isoflavones including glycitein improve glycemic control in diabetic animal models and in clinical meta-analyses of type 2 diabetes patients. Mechanisms include inhibition of alpha-glucosidase, reduction of postprandial glucose, and modulation of beta-cell function.

Lycium barbarum polysaccharides (LBP) have demonstrated hypoglycemic activity in multiple preclinical models and several human trials. A double-blind, placebo-controlled RCT in 67 type-2 diabetic patients found that 300 mg/day LBP for 3 months significantly increased HDL and improved glycemic markers. Meta-analyses confirm LBP significantly regulates fasting blood glucose. Evidence is promising but human trial sample sizes remain limited.

Berberine, goldenseal's principal alkaloid, has been shown in multiple randomized controlled trials and meta-analyses to reduce fasting glucose, postprandial glucose, and HbA1c in type 2 diabetes patients. The NCCIH notes a key caveat: goldenseal supplements may deliver little bioavailable berberine, so direct extrapolation requires caution.

Multiple small RCTs and a 2023 meta-analysis of RCTs demonstrate that amla supplementation lowers fasting blood glucose and improves glycemic markers in type 2 diabetic and prediabetic patients. One small study reported that 1–3 g amla powder daily for 3 weeks lowered blood sugar in both diabetic and non-diabetic subjects. Evidence is promising but mixed.

Human RCTs and meta-analyses show grape polyphenols—particularly resveratrol and proanthocyanidins from grape seed extract—can modestly improve glycemic markers. A 2011 meta-analysis of 11 RCTs found resveratrol improved glucose tolerance and insulin sensitivity in type 2 diabetics. Grape seed extract has demonstrated antioxidant benefits in T2DM by raising glutathione levels. Greater grape consumption in epidemiological studies is associated with lower T2DM risk.

Multiple RCTs show GSE improves glycemic markers including fructosamine, insulin resistance (HOMA-IR), and insulin concentration. One RCT in 32 T2DM patients (600 mg/day, 4 weeks) significantly reduced fructosamine. A separate RCT in adolescents with metabolic syndrome (8 weeks) found GSE improved insulin concentration and insulin resistance.

Clinical evidence shows that fresh grapefruit consumption does not adversely affect fasting blood glucose or insulin in healthy adults. In a subset of participants with metabolic syndrome, grapefruit consumption was associated with greater reductions in 2-hour insulin levels. The flavonoid naringenin has been proposed to improve glucose handling via intestinal bacterial hydrolysis to active metabolites.

Green chiretta has demonstrated antihyperglycaemic activity in several human and animal studies. An open-label clinical trial in type 2 diabetic patients showed a statistically significant 5.46% reduction in HbA1c. Mechanistic studies show improved insulin sensitivity, GLUT-4 upregulation, and enhanced glucose metabolism.

Green tea has been evaluated in multiple RCTs and meta-analyses for its effects on blood sugar and insulin sensitivity. A meta-analysis of 17 RCTs found green tea supplementation significantly reduced fasting blood glucose. Active constituents include EGCG, other catechins, and L-theanine that collectively improve insulin signaling.

Guarana polyphenols inhibit alpha-glucosidase and alpha-amylase, reducing postprandial glucose rises. Epidemiological data from habitual guarana consumers show lower fasting glucose. Human supplementation studies have reported reductions in fasting glucose and triglycerides. Catechins and epicatechins in guarana improve insulin sensitivity by reducing oxidative damage and inflammation.

Gymnema sylvestre, known as the 'sugar destroyer' in Ayurvedic medicine, has been used for centuries to manage blood sugar in India. A meta-analysis of 10 clinical studies showed significant reductions in fasting blood glucose, postprandial glucose, and HbA1c in T2DM patients. Active gymnemic acids block sweet taste receptors and inhibit intestinal glucose absorption.

Gymnemic acids are the primary active triterpene glycosides in Gymnema sylvestre responsible for its anti-diabetic effects. They block sugar absorption in the intestine, suppress sweet taste perception, and stimulate pancreatic beta-cell regeneration. They are the basis for the herb's traditional name 'sugar destroyer.'

Hawthorn extracts improve glycemic parameters in animal models of type 2 diabetes, primarily via AMPK activation that reduces hepatic gluconeogenesis and improves insulin sensitivity. Limited clinical data—including a study with hawthorn plus metformin—show reductions in fasting blood glucose and HbA1c. Human standalone RCT evidence remains limited.

Several preclinical studies demonstrate antidiabetic activity of H. spicatum essential oil and rhizome extracts in animal models, including blood glucose reduction in streptozotocin-induced diabetic rats. TLC-MS bioautography of hydroalcoholic extracts identified quercetin and beta-sitosterol as active compounds inhibiting α-amylase and α-glucosidase. Evidence remains preclinical with no human trials reported.

Hesperidin/hesperetin has demonstrated glucose-lowering effects in animal models and some human RCTs show reductions in insulin levels at high doses and longer durations. However, pooled meta-analyses have not consistently shown significant effects on fasting blood glucose or HOMA-IR in humans.

Human RCT evidence for hesperidin on fasting blood glucose (FBG) is conditional and dose-dependent. A 2024 updated meta-analysis of RCTs found a small but significant reduction in FBG (WMD: −0.15 mg/dL) and improvement in the quantitative insulin sensitivity check index (QUICKI). Effects are more pronounced at doses >500 mg/day, durations >6 weeks, and in individuals with impaired baseline FBG.

Hibiscus sabdariffa inhibits alpha-glucosidase in vitro and has attenuated postprandial blood glucose and insulin responses in human crossover studies. A 2020 meta-analysis found a modest pooled reduction in fasting plasma glucose (−3.67 mg/dL) across RCTs. Evidence is mixed for chronic glycemic control, with most chronic trials showing limited fasting glucose effects.

In a high-fat diet mouse model, HMRlignan supplementation resulted in a >70% decrease in insulin secretion and insulin resistance compared to untreated high-fat diet controls. Enterolactone and enterodiol, HMR's metabolites, inhibited adipogenesis, which is mechanistically linked to improved insulin sensitivity. No human clinical data specifically for blood glucose are available.

Multiple preclinical studies and one longitudinal meta-analysis of STZ-induced rodent model studies demonstrate blood glucose–lowering effects of H. antidysenterica seed, bark, and leaf extracts. Seed extracts inhibit alpha-glucosidase activity (IC50 0.52 mg/mL, PubMed PMID 21385604). A single human case report documents dramatic fasting glucose reduction. Randomized human trials are still needed.

Multiple clinical trials and systematic reviews have assessed honey's effects on blood glucose. Evidence is mixed: honey may modestly reduce fasting blood glucose and HbA1c in some populations when substituted for refined sugar, but high doses can worsen glycemic control in type 2 diabetes. A 2022 meta-analysis and 2025 umbrella review both note that 10 g/day substituted for simple sugars may positively influence HbA1c.

Multiple preclinical studies demonstrate that L. japonica polysaccharides and flavonoid extracts reduce fasting blood glucose, improve glucose tolerance, and lower LDL-cholesterol in streptozotocin-induced diabetic animal models. Hypoglycemic active components have been identified via UPLC-Q-TOF-MS. Human clinical data are lacking.

Xanthohumol from hops has demonstrated hypoglycemic effects in obese rodent models, reducing fasting plasma glucose and improving insulin sensitivity. A hops-valerian combination product was reported to improve insulin sensitivity in patients with type-2 diabetes in a clinical study. Preclinical evidence is consistent, but human RCT data are limited.

Multiple animal studies show M. vulgare extracts reduce blood glucose in diabetic rodent models, and one small clinical study in type 2 diabetics found modest reductions in plasma glucose after 21 days of horehound tea. Evidence is preliminary and no large RCTs exist, but the hypoglycaemic signal is consistent across preclinical models and one human trial.

Multiple preclinical studies demonstrate antihyperglycemic activity for Lablab purpureus extracts. Methanol and ethanol extracts of seeds and leaves reduce blood glucose in alloxan- and glucose-loaded animal models in a dose-dependent manner. The antidiabetic effect targets the pancreas, serum, and small intestine, partly through alpha-glucosidase inhibition.

Skimmin, a coumarin compound identified as a major active constituent of Hydrangea paniculata, has been studied in vitro and in animal models for its effects on glucose metabolism and insulin resistance. A 2020 study published in Frontiers in Pharmacology demonstrated that skimmin relieved high-fat/high-sugar-induced insulin resistance and enhanced glucose uptake via the PI3K/Akt signaling pathway. These findings are preclinical only, with no human trials conducted.

HCA has been shown to slow intestinal glucose absorption in both healthy humans and type 2 diabetes patients in a double-blind RCT. Animal studies show substantial glucose-lowering effects, though human data are more modest. The mechanism may involve delayed glucose transit and incretin modulation.

Hyssop extracts contain alpha-glucosidase inhibitors that reduce postprandial carbohydrate absorption. Animal and in vitro studies demonstrate inhibition of sucrase and maltase activity in intestinal preparations, and hypoglycemic effects in diabetic rat models. No human clinical trials have confirmed these effects directly.

In vitro studies show that Impatiens balsamina seed extract exhibits significant antidiabetic activity via alpha-amylase inhibition, with an IC50 of 0.316 mg/mL — comparable to the reference drug acarbose. Anthocyanins and triterpenoids are identified as the responsible constituents.

Multiple animal studies and at least two human-relevant trials demonstrate that bael leaf and fruit extracts lower fasting blood glucose, improve oral glucose tolerance, and reduce HbA1c in diabetic models. Mechanisms include alpha-amylase inhibition, stimulation of insulin secretion, and retardation of intestinal glucose absorption. Limited human clinical data supports these findings.

Multiple clinical trials have examined Boswellia gum resin in type 2 diabetes patients. A double-blind RCT (Azadmehr et al., 2014, Iran J Pharm Res) found Boswellia to act as an anti-oxidant, anti-hyperglycaemic, and anti-hyperlipidaemic agent in type 2 diabetic patients. A 2024 systematic review and meta-analysis confirmed evidence across several RCTs, though results are inconsistent.

Human clinical trials demonstrate that gum arabic supplementation reduces fasting plasma glucose in metabolic syndrome and diabetic populations. In vitro studies confirm alpha-glucosidase and alpha-amylase inhibition by A. nilotica extracts. The 12-week RCT by Jarrar et al. showed significant reductions in fasting plasma glucose.

Multiple in vivo animal studies have demonstrated significant hypoglycemic activity of H. indicus root extracts. A key PMC-indexed study showed that aqueous root extract at 500 mg/kg/day significantly lowered blood glucose in streptozotocin-induced diabetic rats and normalized related metabolic parameters. No controlled human trials have been published to date.

Multiple preclinical and some clinical studies support antidiabetic activity. Clinical trials in type 2 diabetics report reduced fasting blood glucose with T. cordifolia extract. The alkaloid berberine and the diterpenoid tinosporaside have been shown to augment GLUT4 translocation and activate AMPK in skeletal muscle, providing a mechanistic basis. WebMD/RxList summarize that taking it 'by mouth seems to improve blood sugar in adults with type 2 diabetes.'

Inositol (particularly myo-inositol and D-chiro-inositol) functions as a second messenger in insulin signaling. A systematic review and meta-analysis of RCTs concluded that inositol supplementation significantly decreases blood glucose through improvements in insulin sensitivity, independent of weight change.

Root powder of I. racemosa is reportedly hypoglycemic in human subjects, cited across multiple peer-reviewed reviews. Animal experiments comparing I. racemosa with Saussurea lappa on blood glucose in albino rats confirm hypoglycemic activity. In combination with Gymnema sylvestre, it reduced corticosteroid-induced hyperglycemia in mice.

A GRADE-assessed meta-analysis of 33 RCTs found ITF supplementation significantly reduces fasting blood glucose and HbA1c in people with prediabetes and type 2 diabetes. Effects are clinically meaningful in diabetic populations but minimal in normoglycemic individuals. The primary mechanism is SCFA-driven GLP-1 stimulation and improved gut microbiota composition.

Invertase (sucrase) hydrolyzes sucrose into glucose and fructose at the small intestinal brush border, directly governing the rate and magnitude of postprandial glucose entry into the bloodstream. Inhibiting invertase activity is recognized as a strategy to blunt postprandial blood glucose rises. Efficient sucrase activity is therefore intrinsically tied to glycemic response after sucrose-containing meals.

Isoleucine has demonstrated a specific, insulin-independent hypoglycemic effect distinct from the other BCAAs. Human and animal studies show it lowers postprandial blood glucose by increasing skeletal muscle glucose uptake. This mechanism is unique to isoleucine among the three BCAAs.

IMO elicits a lower postprandial glycemic response than dextrose, though it is not entirely non-digestible. Small human trials show modest reductions in fasting plasma glucose when IMO is combined with high-protein diets. EFSA has reviewed glycemic claims for IMO. The evidence suggests partial benefit, with the caveat that IMO has a measurable glycemic impact.

Multiple human clinical trials demonstrate that jiaogulan tea significantly lowers fasting blood glucose and HbA1c in type 2 diabetic patients, primarily by improving insulin sensitivity. A 12-week RCT (n=24) found a ~3.0 mmol/L reduction in fasting glucose and ~2% decrease in HbA1c vs. controls.

Multiple human RCTs and a systematic review/meta-analysis have assessed jujube fruit on fasting plasma glucose in type 2 diabetics. A 12-week RCT (n=48, T2D) found dried jujube (30 g/day) significantly reduced fasting plasma glucose by ~11%. A meta-analysis of RCTs confirmed beneficial effects on glycemic index. Evidence is promising but based on small trials predominantly from Iran.

The Kyushu University prospective study found 8 weeks of daily kale powder reduced fasting blood glucose in adults with potential metabolic syndrome. Kale's low glycemic index, high fiber content, and glucosinolate-derived compounds are proposed mechanisms. Evidence from mouse models of insulin resistance also shows metabolic improvement with kale supplementation.

Clinical and meta-analytic evidence supports brown seaweed/kelp components in lowering blood glucose. A 2023 meta-analysis of 23 studies found significant improvements in postprandial glucose, HbA1c, and HOMA-IR in seaweed groups. Kelp's fucoidan, alginate, and vanadium content are implicated mechanistically. Evidence is encouraging but studies remain small and heterogeneous.

Kidney beans have a very low glycemic index due to their high resistant starch, slowly digestible starch, soluble fiber, and alpha-amylase inhibitor (phaseolamin) content. Clinical trials in healthy adults and type 2 diabetic subjects show meaningful reductions in postprandial blood glucose and insulin. Regular pulse consumption also improves longer-term markers such as fasting glucose and HbA1c.

Multiple meta-analyses of RCTs confirm resveratrol significantly improved fasting plasma glucose and insulin levels in type 2 diabetes patients. A 9-RCT meta-analysis showed resveratrol reduced fasting glucose by −0.29 mmol/L (p<0.01). Emodin from knotweed regulates glucose metabolism via AMPK pathways. Evidence specifically for PC-derived resveratrol is limited but mechanistically consistent.

A 2025 RCT in MDD adults found krill oil supplementation significantly reduced HbA1c compared to baseline, an effect not observed with fish oil or placebo. An independent RCT also reported a significant decrease in fasting blood glucose in the krill group. A 2023 updated meta-analysis of cardiovascular RCTs found no significant overall effect on blood glucose across trials, indicating results are mixed.

Puerarin, kudzu's primary isoflavone, has demonstrated hypoglycemic activity in multiple preclinical models and limited clinical research. It appears to act via PTP1B pathway inhibition, improved insulin sensitivity, and enhanced glucose uptake into muscle. A clinical trial in type 2 diabetics using oral puerarin plus rosiglitazone showed significantly reduced blood glucose and HbA1c versus baseline.

L-Alanine is the primary gluconeogenic amino acid and a central regulator of blood glucose via the glucose-alanine (Cahill) cycle. Human clinical data show it can raise blood glucose during hypoglycemia in insulin-dependent diabetes. Animal studies also demonstrate significant blood glucose lowering in diabetic models, possibly via hepatic AMPK activation.

IV alanyl-L-glutamine has been shown to balance glucose-insulin homeostasis in patients undergoing major surgery. An RCT demonstrated that perioperative IV AG improved insulin resistance index and insulin sensitivity in colon cancer resection patients. Additional clinical data support AG's role in attenuating surgical hyperglycemia and insulin resistance in critically ill patients.

Multiple RCTs and a 2020 meta-analysis of randomized controlled trials found that L-arginine supplementation significantly reduced fasting blood glucose (WMD: −3.35 mg/dL) and serum insulin levels. Effects were strongest at doses >6.5 g/day and in non-diabetic participants with elevated baseline insulin. Overall clinical meaningfulness is considered modest by reviewers.

Multiple RCTs and meta-analyses show L-carnitine supplementation reduces fasting blood glucose and HbA1c in diabetic patients. A 2022 systematic review of 17 RCTs (n=1,622) found significant reductions in FBG (WMD −0.46 mmol/L) and HbA1c (WMD −0.5%). A euglycemic hyperinsulinemic clamp study demonstrated improved whole-body insulin-mediated glucose uptake in type 2 diabetics.

Multiple RCTs show that L-carnosine supplementation (1–2 g/day for 12–14 weeks) reduces post-load blood glucose and attenuates increases in fasting insulin and insulin resistance. Effects are seen in overweight non-diabetic individuals and in patients with pre-diabetes or type 2 diabetes. Mechanisms include antiglycation activity and possible modulation of hepatic glucose output.

L-cysteine levels are consistently lower in type 2 diabetic patients, and supplementation has been shown to lower blood glucose and glycated hemoglobin in diabetic animal models. Human observational data show positive correlations between L-cysteine/GSH levels and insulin sensitivity. The relationship is complex: elevated plasma L-cysteine has also been associated with insulin resistance in some epidemiological datasets.

L-glutamine is a potent GLP-1 secretagogue in vitro, and clinical evidence shows it reduces postprandial glycemia in type 2 diabetes patients when taken with meals. A randomized crossover trial demonstrated that 15 g doses before meals increased GLP-1 and insulin excursions and lowered postprandial blood glucose.

Multiple randomized clinical trials have demonstrated that oral L-glutathione supplementation improves markers of blood sugar control in diabetic and obese individuals. One six-month RCT in 250 T2D patients showed significant reductions in HbA1c and oxidative DNA damage. A separate 3-week double-blind trial found significantly improved whole-body insulin sensitivity measured by hyperinsulinemic-euglycemic clamp.

Lower circulating glycine is consistently observed in type 2 diabetes and obesity, and clinical trials suggest glycine supplementation can improve fasting glucose and postprandial glycemic control. A 5 g oral dose has been shown to increase insulin secretory responses, and RCT evidence supports modest reductions in HbA1c in metabolic syndrome patients. Effects are adjunctive rather than pharmacological.

L-histidine supplementation has been shown in human RCTs to reduce insulin resistance (HOMA-IR) in obese women with metabolic syndrome. Brain histamine derived from histidine also reduces hepatic glucose output via a neural liver signal. Cross-sectional data associate higher dietary histidine intake with lower fasting blood sugar and improved insulin sensitivity in obese subjects.

Multiple human clinical studies demonstrate that orally administered isoleucine can lower postprandial blood glucose levels. In healthy subjects, isoleucine reduced blood glucose area under the curve in response to a mixed-nutrient drink. The mechanism appears distinct from insulin stimulation, involving enhanced peripheral glucose removal.

Leucine stimulates insulin secretion from pancreatic beta cells via two biochemical pathways and, when co-ingested with glucose, substantially attenuates postprandial blood glucose excursions. A clinical crossover in 13 healthy subjects found leucine plus glucose reduced the 2.5-hour glucose area response by 50% versus glucose alone. Leucine also increases in vivo insulin levels and improves glycemic control in diabetic animal models.

L-phenylalanine lowers postprandial blood glucose in both animal and human studies, through stimulation of insulin release and gut hormones including CCK and PYY. A randomized double-blind crossover trial in humans demonstrated reduced postprandial glycemia following intragastric L-Phe administration. Mechanistic research also identifies a potential risk at chronically elevated phenylalanine levels impairing insulin receptor signaling.

The relationship between L-valine and blood sugar is complex and bidirectional. Elevated circulating valine is associated with insulin resistance and type 2 diabetes risk in human epidemiological studies. Valine's catabolite 3-HIB has been shown to impair muscle insulin signaling in human subjects. Conversely, in animal models, dietary valine restriction improved glucose tolerance, suggesting valine excess may negatively affect blood sugar regulation.

Higher LA biomarker levels are associated with dose-dependent decreases in type 2 diabetes incidence across a pooled analysis of 20 global studies. Intervention trials show biomarkers of LA intake are linked to better glycemic control and improved insulin sensitivity, particularly when LA-rich diets substitute for saturated fat.

A parallel RCT (n=226 GDM patients, 40 weeks) found that L. bulgaricus fermented black garlic significantly reduced fasting and post-load blood glucose levels and improved insulin resistance compared to black garlic alone. Multi-strain probiotic formulations containing L. bulgaricus have been associated with improvements in serum glucose, HbA1c, and HOMA-IR in T2DM patients across multiple RCTs.

L. casei LC2W was evaluated in a 2024 RCT in subjects at high risk of metabolic syndrome for effects on glucose metabolism. Broader meta-analyses of Lactobacillus supplementation in overweight/obese adults report modest glycemic improvements. Mechanistically, L. casei modulates gut microbiota composition and SCFA production relevant to glucose homeostasis.

Clinical and preclinical evidence supports a role for L. gasseri in glucose regulation. The strain BNR17 was assessed in a 12-week RCT in overweight adults with elevated fasting blood sugar, and animal studies show multiple strains improve glucose tolerance and reduce fasting blood glucose. Mechanistic data point to short-chain fatty acid production and reduced gut-derived inflammation as drivers of improved glycemic control.

L. paracasei HII01 was tested in a randomized, double-blind, placebo-controlled trial in type 2 diabetic patients over 12 weeks, demonstrating significant reduction in fasting blood glucose and inflammatory markers. Animal and in vitro studies with multiple L. paracasei strains show inhibition of α-glucosidase, enhanced GLUT4 expression, and improved insulin signaling.

A systematic review and meta-analysis of RCTs found L. plantarum supplementation significantly reduced fasting plasma glucose and HbA1c in people with type 2 diabetes or prediabetes. Effects on HOMA-IR trended positive but did not always reach statistical significance.

Clinical trials show L. rhamnosus supplementation can stabilize glycemic markers in at-risk populations. A 90-day placebo-controlled RCT demonstrated that LGG prevented an increase in HbA1c in middle-aged adults (p=0.005). The HN001 strain in pregnancy reduced conjugated bile acids and improved glucose metabolism in women at risk for gestational diabetes.

Lemon juice has demonstrated acute glycemic-response reduction in a clinical RCT. A randomized crossover trial found that lemon juice significantly reduced the glycemic response to bread in healthy volunteers. Citrus flavonoid extracts from lemon reduced blood glucose and insulin resistance markers in prediabetic patients.

An exo-polymer from L. edodes mycelial submerged cultures reduced plasma glucose by 21.5% and increased plasma insulin by 22.1% in diabetic rats. A mycelial polysaccharide also protected pancreatic beta cells from high-glucose-induced damage via MAPK and Nrf2 pathways in vitro. Evidence is currently preclinical only.

A randomized double-blind crossover trial in 73 type 2 diabetic patients found 360 mg/day SDG for 12 weeks significantly improved HbA1c compared to placebo. A 2024 analysis of US prospective cohorts suggested higher lignan intake may lower type 2 diabetes risk by up to 27%, particularly in obese and premenopausal women. Meta-analyses of flaxseed supplementation confirm significant reductions in fasting blood glucose, insulin, HbA1c, and HOMA-IR in people with prediabetes and type 2 diabetes.

Multiple preclinical studies demonstrate that lily bulb polysaccharides and steroidal glycosides (regalosides) inhibit α-glucosidase and α-amylase, lowering postprandial blood glucose. In hyperglycemic mouse models, regaloside B reduced blood glucose from ~28 mmol/L to ~14 mmol/L. Polysaccharides also promote hepatic glycogen synthesis and increase glucose uptake in adipocytes. No controlled human clinical trials have been published to date.

Lime's flavonoids—hesperidin, diosmin, and naringin—have demonstrated blood-glucose-lowering activity in animal models via PI3K/AKT/FOXO1 insulin signaling pathways. A human RCT using lime plus cumin found significant reductions in fasting plasma glucose and improvements in insulin sensitivity. Pectin in lime pulp may also blunt post-meal glucose spikes.

Preclinical evidence consistently shows D-limonene lowers fasting blood glucose and HbA1c in diabetic animal models, enhancing antioxidant enzymes such as SOD and catalase. In high-fat diet and hypertensive rat models, D-limonene supplementation reversed elevated fasting blood glucose and restored hepatic and pancreatic pathology. No controlled human trials have yet been conducted, so evidence remains at the preclinical stage.

Animal studies show Lion's Mane extracts lower blood glucose via alpha-glucosidase inhibition and improved insulin sensitivity. In vitro antidiabetic activity (aldose reductase and alpha-glucosidase inhibition) is documented. No human clinical trials on glycemic control have been published.

Preclinical studies in T2DM mouse models show L. gracile extract improves glucose tolerance, insulin resistance, and lipid metabolism, with isoorientin, orientin, and isovitexin as key active components. The mechanism involves the gut microbiota–SCFA–inflammatory response axis. No human clinical trials are available.

Lotus plumule polysaccharide shows antidiabetic effects by modulating pancreatic islet function and inflammatory cytokines in diabetic mice. Lotus plant extracts broadly show hypoglycemic activity in animal models. The lotus leaf has been used in Chinese herbal teas for blood sugar control; lotus seed-specific human evidence is absent.

Luteolin has demonstrated blood glucose-lowering effects in animal models of diabetes and in a human RCT using a luteolin-containing nutraceutical combination. It acts via multiple mechanisms including improved insulin signaling and reduced hepatic lipid accumulation. Some human evidence exists from combination product trials.

Lychee seed (Li Zhi He) is a documented traditional Chinese medicine for blood sugar modulation with several supporting clinical observations and animal studies. Oligonol (lychee-derived polyphenol) has shown support for post-meal blood glucose levels in human studies. A Frontiers review confirmed the antidiabetic effects of lychee seed have been validated by clinical observations in addition to preclinical work.

Clinical meta-analyses of tree nut interventions including macadamia nuts show modest improvements in glycemic control. A meta-analysis of 12 RCTs found tree nuts (including macadamias) at ~56 g/day significantly decreased HbA1c and fasting glucose in type 2 diabetes. Macadamia nuts' low glycemic index, high MUFA, and fiber content slow glucose absorption and blunt postprandial glucose spikes.

Magnesium is an essential mineral involved in over 300 enzymatic reactions, including glucose metabolism and insulin signaling. Multiple systematic reviews and meta-analyses of RCTs confirm that magnesium supplementation significantly reduces fasting blood glucose and modestly improves HbA1c in T2DM patients, particularly those with low baseline magnesium.

Multiple preclinical studies demonstrate maitake extracts lower circulating glucose in insulin-resistant animal models. A small human case series reported significant fasting blood glucose reductions in type 2 diabetic patients taking the SX-fraction. The proposed mechanism involves alpha-glucosidase inhibition and enhanced insulin receptor signaling. Human clinical evidence remains limited but directionally consistent.

Vasicine inhibits α-amylase and α-glucosidase in vitro, and A. vasica extract has shown blood glucose-lowering effects in animal models. Vasicine's antidiabetic activity has been demonstrated in multiple in vitro assays and in silico binding studies targeting key glycemic enzymes.

Multiple population-based studies associate lower blood manganese with higher rates of diabetes and impaired glucose regulation. Manganese acts as a cofactor for pyruvate carboxylase and phosphoenolpyruvate carboxykinase, enzymes critical for gluconeogenesis, and may potentiate insulin action. Evidence is observational and sex-specific; intervention trials in humans are sparse.

Multiple randomized controlled trials show mango consumption improves glycemic control. A 24-week RCT in prediabetic adults found daily mango (300 g) lowered fasting glucose and improved insulin sensitivity compared to a calorie-matched control. An 8-week RCT in type 2 diabetics found fasting blood glucose reductions of 26–36 mg/dL versus a bread comparator.

A 2018 prospective RCT in 22 obese insulin-resistant women found mangosteen extract (400 mg/day for 26 weeks) reduced HOMA-IR by 53.2% versus 15.2% in controls. γ-Mangostin activates AMPK/PPARγ pathways to lower blood glucose in animal models. A systematic review (2026) identified only two qualifying human studies, both showing promising but preliminary glycemic benefits.

Circulating mannose levels correlate strongly with fasting plasma glucose and insulin resistance in human studies, establishing mannose as a validated biomarker of glucose dysregulation. A human supplementation study found that short-term oral mannose did not adversely affect glucose tolerance, and mannose has a characteristically flat post-ingestion plasma curve compared to glucose. The evidence relates primarily to endogenous mannose as a biomarker rather than exogenous supplementation improving blood sugar control.

Multiple human clinical trials demonstrate that standardized maqui berry extract (Delphinol®) significantly reduces postprandial blood glucose and lowers HbA1c in prediabetic individuals. The primary mechanism is inhibition of the intestinal sodium-glucose cotransporter SGLT1, slowing glucose absorption. A 3-month open trial in 31 prediabetic adults showed HbA1c falling from 5.65% to 5.35% (p=0.003). Acute crossover studies confirm dose-dependent reductions in postprandial glycemia and insulinemia.

A randomized controlled pilot study found that marjoram tea taken twice daily for one month significantly reduced fasting insulin levels in women with PCOS. Preclinical studies support antidiabetic activity, and marjoram has long been used in Moroccan folk medicine as an antidiabetic agent.

The CHIOS-MASTIHA RCT (n=179 healthy volunteers) found that 1 g/day crude mastic gum for 8 weeks significantly reduced fasting plasma glucose by 4.5 mg/dL (p<0.05), with stronger effects in overweight/obese individuals. An earlier 18-month human study (5 g/day) demonstrated reductions in multiple metabolic markers. Animal data consistently confirm hypoglycemic activity.

Clinical evidence suggests MCT supplementation may modestly improve insulin-mediated glucose metabolism and reduce postprandial glucose in some populations, particularly those with insulin resistance or type 2 diabetes. A 6-week RCT in non-diabetic adults found wide inter-individual variability in insulin sensitivity outcomes with ~40 g/day MCT. MCTs do not raise blood glucose on their own; when co-ingested with glucose, blood glucose and insulin rise as expected from the carbohydrate.

Multiple RCTs and meta-analyses show silymarin reduces fasting blood glucose and HbA1c in type 2 diabetes patients. A meta-analysis of 7 studies (370 patients) found silymarin decreased fasting glucose by ~38 mg/dL and HbA1c by ~1.4%. A second meta-analysis of 16 studies (1,358 patients) confirmed reductions in fasting glucose, HbA1c, and LDL cholesterol.

Multiple meta-analyses and clinical trials demonstrate that millet seed consumption reduces fasting and post-prandial blood glucose. The mean glycemic index of millets is approximately 52.7, about 36% lower than refined rice or wheat. A self-controlled clinical trial of foxtail millet over 12 weeks significantly reduced fasting and 2-hour post-load glucose in subjects with impaired glucose tolerance.

Momordica charantia (bitter melon/bitter gourd) is widely used in traditional medicine across Asia, Africa, and the Caribbean for blood sugar management. It contains multiple bioactive compounds with confirmed anti-diabetic properties. Clinical trials in T2DM patients show reductions in fasting glucose and HbA1c, though evidence is variable.

Monk fruit extract (MFE) has a zero glycemic index because mogrosides are not absorbed as carbohydrates and do not raise blood glucose. Clinical trials demonstrate significant reductions in postprandial glucose and insulin response when MFE replaces sugar. In vitro and animal studies show mogroside V stimulates insulin secretion from pancreatic beta cells. Human RCT evidence, while still limited in scale, consistently confirms glycemic neutrality or benefit.

M. officinalis root extract has demonstrated antidiabetic activity in high-fat diet/streptozotocin-induced diabetic mouse models, improving blood glucose, insulin, and lipid parameters. M. citrifolia has been documented for diabetes across multiple traditional medicine systems and shows antidiabetic activity in animal models.

Morus alba leaf extract is one of the most clinically studied herbal interventions for blood glucose regulation. The alkaloid 1-deoxynojirimycin (DNJ) inhibits intestinal α-glucosidase, blunting postprandial glucose spikes. Multiple RCTs in prediabetic, diabetic, and normoglycaemic adults confirm reductions in fasting glucose, postprandial glucose, and HbA1c.

Mulberry leaf extract is one of the most robustly studied herbal interventions for postprandial blood glucose. Multiple randomised controlled trials in healthy adults and type 2 diabetics demonstrate significant reductions in post-meal glucose and insulin. The key active compound is 1-deoxynojirimycin (DNJ), an α-glucosidase inhibitor. A 2025 meta-analysis of 15 RCTs (n=1,202) confirmed improvements in fasting glucose and HbA1c.

Human and animal evidence supports mustard's role in glycemic regulation. A Cardiff Metropolitan University study in pre-diabetic patients found that a heaped teaspoon of wholegrain mustard taken nightly reduced fasting blood glucose and cholesterol. Glucosinolate-derived isothiocyanates and omega-3 fatty acids in mustard seeds have been shown to improve insulin sensitivity in animal models. Clinical evidence remains preliminary but promising.

TC extracts inhibit alpha-glucosidase and alpha-amylase, and reduce fasting blood glucose and HbA1c in animal models of type 2 diabetes. A 3-month RCT in diabetic women (TC combined formula) showed significant reductions in fasting glucose and HbA1c versus placebo. One 12-week human RCT also evaluated TC monotherapy effects on glycosylated haemoglobin.

Animal studies show myrrh lowers blood glucose levels significantly, from a mean of 16.7 mmol/L to 8.5 mmol/L in a diabetic rat model. A review concluded evidence for human diabetes management is preliminary. The combination of Commiphora mukul, C. myrrha, and Terminalia chebula showed anti-diabetic and antioxidant effects in diabetic rats.

Clinical evidence indicates NAC can reduce fasting plasma glucose and insulin resistance markers in metabolic populations. An RCT in 76 patients with metabolic syndrome found 1800 mg/day NAC for 12 weeks significantly reduced fasting glucose, fasting insulin, and insulin resistance index. Animal data strongly support antidiabetic effects, though human trial results are mixed and context-dependent.

Naringin and its aglycone naringenin improve insulin sensitivity and glucose metabolism via activation of GLUT-4 and PPAR-γ. A clinical case study found 150 mg naringenin three times daily for 8 weeks reduced fasting insulin by 18% in a diabetic subject. Blood naringenin levels in population studies correlate inversely with insulin resistance. Human clinical evidence remains preliminary, largely supported by robust preclinical data.

A published RCT (n=80 T2DM patients, 12 weeks) found that aqueous neem leaf/twig extract at 125–500 mg twice daily significantly improved fasting blood sugar, postprandial blood sugar, and HbA1c versus placebo, all on background metformin therapy. A second RCT in metabolic syndrome subjects corroborated these findings. Proposed mechanisms include α-glucosidase and α-amylase inhibition by the bioactive meliacinolin, and modulation of serotonin-mediated insulin release.

Multiple RCTs and a systematic review with meta-analysis support nettle leaf extract's ability to reduce fasting blood glucose, postprandial glucose, and HbA1c in type 2 diabetes patients. A 2013 double-blind RCT (Kianbakht et al.) found significant reductions in all three glycemic markers versus placebo. A meta-analysis of eight RCTs confirmed significant lowering of fasting blood sugar in T2DM. Proposed mechanisms include alpha-glucosidase inhibition, GLUT-2 upregulation, enhanced insulin secretion, and reduced intestinal glucose absorption.

A landmark 10-week RCT in prediabetic postmenopausal women found NMN (250 mg/day) improved muscle insulin sensitivity and muscle NAD+ turnover. However, a 2024 meta-analysis of 8 RCTs found no significant pooled effect of NMN on fasting glucose, fasting insulin, or HbA1c in predominantly non-diabetic adults. Evidence is mixed and population-specific.

Multiple small human trials and a systematic review indicate nopal (Opuntia ficus-indica) cladodes can meaningfully reduce postprandial blood glucose in people with type 2 diabetes. The effect is strongest for broiled nopal stems (500 g), producing approximately 17.6% reductions in serum glucose at 180 minutes. Capsule and juice forms have shown inconsistent results. Evidence is limited by small sample sizes and lack of large RCTs.

Multiple animal studies demonstrate that C. rotundus rhizome extracts lower blood glucose in alloxan- and streptozotocin-induced diabetic models. Mechanistically, the plant inhibits alpha-glucosidase and alpha-amylase, slowing carbohydrate absorption. Human clinical evidence remains limited, but preclinical data consistently support anti-hyperglycemic activity.

Oat β-glucan reduces postprandial blood glucose by slowing gastric emptying and nutrient absorption through viscosity. Meta-analyses of RCTs confirm significant reductions in fasting glucose and HbA1c in type 2 diabetics. EFSA has approved a health claim for oat β-glucan (≥4 g per meal) reducing postprandial glycemia.

Multiple RCTs and meta-analyses confirm okra reduces fasting blood glucose and HbA1c in prediabetes and type 2 diabetes patients. A 2024 Frontiers in Nutrition meta-analysis of nine RCTs found significant reductions in FBG (WMD: −39.58 mg/dL) and HbA1c (WMD: −0.46%). The primary mechanisms involve soluble mucilage slowing intestinal glucose absorption and polyphenols inhibiting digestive enzymes such as α-glucosidase.

Oleanolic acid (OA) reduces hyperglycemia in animal models by suppressing hepatic gluconeogenesis via the Akt/FoxO1 axis and inhibiting alpha-glucosidase. It enhances insulin sensitivity and supports pancreatic beta-cell function. A 2022 systematic review confirmed these mechanisms across 13 animal studies and 3 cell experiments, though human RCTs remain scarce.

Oleic acid-rich diets have been associated with modest improvements in fasting glucose and insulin sensitivity in human studies, particularly in diabetic and at-risk populations. A PubMed-indexed study found a small but significant decrease in fasting glucose/insulin ratio following an oleic acid-rich dietary intervention. A 2021 systematic review found olive oil and oleic acid intake associated with beneficial effects on components of metabolic syndrome including glucose control.

Olive leaf polyphenols, particularly oleuropein and hydroxytyrosol, have documented effects on insulin sensitivity in human trials. A PLOS ONE RCT found a 15% improvement in insulin sensitivity and 28% improvement in pancreatic beta-cell responsiveness in overweight men after 12 weeks of OLE. The evidence is strongest for at-risk, overweight individuals rather than normoglycemic populations.

Clinical trials confirm EVOO reduces postprandial glucose excursions and improves fasting blood glucose and HbA1c. PREDIMED data show Mediterranean diet with EVOO prevents diabetes onset. Olive oil polyphenols modulate alpha-glucosidase activity and enhance insulin signaling.

Omega-3 fatty acids have been studied extensively for glycemic control in type 2 diabetes, with mixed but meaningful results. A 2022 meta-analysis of 46 RCTs found beneficial effects on glycemic control and triglycerides in T2DM. Earlier meta-analyses found significant triglyceride lowering but no consistent effect on HbA1c or fasting glucose, indicating context-dependent efficacy.

The evidence for omega-6 fatty acids specifically in blood sugar control is mixed. Replacing saturated fat with PUFA (including omega-6) has been associated with improved glycemic control and reduced insulin resistance across meta-analyses. However, large systematic reviews of omega-6 supplementation trials specifically find little independent effect on fasting glucose, HbA1c, or HOMA-IR. The Multi-Ethnic Study of Atherosclerosis found complex, race-dependent associations between omega-6 species and insulin levels.

Palmitoleic acid exhibits hormone-like properties and has been associated with improved glucose metabolism in observational human studies. The RISC cohort study (Diabetologia, 2019) found circulating palmitoleate to be an independent determinant of insulin sensitivity and glucose tolerance in non-diabetic individuals. Animal models robustly support glucose-lowering effects, but dedicated human interventional trials with glucose as a primary endpoint are still underway.

Oleic acid (omega-9) supports glycemic regulation by enhancing insulin sensitivity and facilitating adipocyte glucose transport. Mediterranean diets rich in OA are associated with improved fasting glucose and reduced type 2 diabetes risk. Mechanistic studies confirm OA prevents saturated-fat-induced dysregulation of glucose metabolism.

Multiple human clinical trials have demonstrated that onion consumption reduces fasting blood glucose levels in diabetic patients. Organosulfur compounds (notably S-methyl cysteine sulfoxide) and quercetin in onion regulate carbohydrate-metabolizing enzymes and enhance insulin secretion and sensitivity. A preliminary clinical trial in type 1 and type 2 diabetic patients showed significant hypoglycemic effects from 100 g fresh onion.

Polysaccharides and oligosaccharides from Ophiopogon japonicus have demonstrated hypoglycemic effects in multiple rodent models of type 2 diabetes. The polysaccharide MDG-1 activates the PI3K/Akt signaling pathway to improve insulin sensitivity, while oligosaccharides (OJO/OOJ) reduce fasting blood glucose and improve glucose tolerance. Evidence is preclinical; no robust human RCTs have been published.

Multiple preclinical studies demonstrate that polysaccharides and oligosaccharides from ophiopogon root lower blood glucose in diabetic animal models. The fructan MDG-1 activates the PI3K/Akt insulin-signaling pathway and significantly reduces fed blood glucose in KKAy and ob/ob mouse models. Oligosaccharide fractions also improve oral glucose tolerance and reduce fasting blood glucose in streptozotocin/high-fat-diet-induced type 2 diabetic rats. Human clinical evidence remains limited, but the mechanistic and animal data are substantial.

Orange-derived hesperidin modulates intestinal glucose transport and has been studied in human RCTs for glycaemic effects. A 2024 meta-analysis of 12 RCTs found significant reductions in fasting blood glucose and improvements in insulin sensitivity index with hesperidin supplementation. However, the magnitude of effect is modest and evidence quality ranges from moderate to very low.

Berberine, Oregon grape's primary active alkaloid, has been evaluated in numerous RCTs in type 2 diabetic patients and consistently reduces fasting plasma glucose, postprandial glucose, and HbA1c. Multiple systematic reviews and meta-analyses confirm significant glycemic benefits. These findings are for isolated berberine, not Oregon grape whole-root preparations directly, but Oregon grape is a recognized berberine source.

Aqueous and ethyl acetate extracts of P. orientalis leaves have demonstrated hypoglycemic and alpha-glucosidase inhibitory activity in preclinical models. Polysaccharides isolated from the plant are documented to have hypoglycemic activity. A 2026 Frontiers in Pharmacology study confirmed cardioprotective effects in a diabetic cardiomyopathy murine model alongside blood glucose monitoring.

Multiple preclinical studies show that Oryza sativa bran extracts and pigmented rice varieties inhibit carbohydrate-digesting enzymes (maltase, sucrase) and reduce postprandial blood glucose in diabetic animal models. A human randomized double-blind placebo-controlled study found rice bran triterpenoids improved postprandial hyperglycemia in healthy adults.

Multiple human clinical trials show oyster mushroom consumption significantly reduces fasting and postprandial blood glucose. A 2020 systematic review in Nutrients (8 trials) found consistent beneficial effects on glucose metabolism. A BIRDEM Hospital RCT (89 subjects with T2DM) reported reductions in fasting plasma glucose of ~22–23%. Traditional use in Asian medicine also recognizes the hypoglycemic effect.

P. foetida exhibits antidiabetic and antihyperglycemic activity in multiple preclinical models. Extracts inhibit α-amylase and α-glucosidase enzymes, reduce blood glucose in streptozotocin-induced diabetic rats, and protect the diabetic kidney via NF-κB inhibition. Antihyperlipidemic effects in diabetic models have also been reported.

Palm oil's tocotrienol-rich fraction (TRF) has demonstrated improvements in blood glucose and insulin sensitivity in clinical studies, particularly in subjects with type 2 diabetes, prediabetes, and metabolic syndrome. Animal studies additionally show TRF can reverse hyperglycemia and reduce glycated hemoglobin. The mechanism involves antioxidant suppression of oxidative stress that impairs insulin signaling.

Multiple prospective cohort studies and a meta-analysis of 16 studies associate higher POA levels with lower risk of incident type 2 diabetes. Interventional trials in animal models consistently show improved glucose tolerance; dedicated human RCTs targeting blood glucose are underway.

Several open clinical studies examined pantethine specifically in diabetic patients with dyslipidemia and found it improved lipid profiles without adverse effects on glucose control. Animal and mechanistic evidence suggests pantethine may reduce insulin resistance and hyperglycemia via CoA-dependent metabolic pathways. However, dedicated human RCTs targeting glucose as a primary endpoint have not been published; the evidence in this domain is preliminary.

Multiple preclinical studies and at least one small human study support a blood-glucose-lowering effect of papaya preparations. Fermented papaya preparation (FPP) produced a significant decrease in plasma glucose in both healthy subjects and type-2 diabetic patients in a published clinical observation. Bioactive compounds including flavonoids, saponins, and alkaloids are proposed to inhibit alpha-amylase and alpha-glucosidase and support pancreatic beta-cell insulin release.

Parsley extract has demonstrated hypoglycaemic and anti-diabetic effects in multiple animal models, reducing blood glucose, improving pancreatic function, and protecting the liver in streptozotocin-induced diabetic rats. The mechanisms involve flavonoid-mediated antioxidant and insulin-sensitising actions. Human clinical evidence is lacking.

Human clinical trials show pea protein co-ingested with carbohydrates significantly reduces postprandial blood glucose. A 2026 RCT found 20 g pea protein reduced glucose iAUC by ~37% versus glucose alone. Pea fiber also slows intestinal glucose absorption.

Peach polyphenols and leaf extracts have demonstrated hypoglycemic effects in multiple animal models, including type 2 diabetic mice and high-fructose rats. Mechanisms include α-amylase inhibition, improved insulin sensitivity, and promotion of glycogen synthesis. Human clinical evidence is lacking.

Peanuts have a low glycaemic index and several trials show they moderate postprandial glucose responses. A meta-analysis of 40 RCTs found nut/peanut consumption significantly reduced HOMA-IR and fasting insulin. Peanut butter added to a high-carbohydrate breakfast attenuated blood glucose excursions in obese women.

Pears have a low glycemic index (GI ~30–50) and are rich in dietary fiber and polyphenols including chlorogenic acid, which slow glucose absorption and may reduce postprandial blood sugar rises. Epidemiological data links pear/apple intake to lower risk of type 2 diabetes. Anthocyanins in red-skinned varieties are associated with improved blood vessel function relevant to glycemic control.

Pectin has demonstrated measurable reductions in postprandial blood glucose and fasting glucose in clinical and preclinical research. Its gel-forming properties slow carbohydrate digestion and glucose absorption. Human studies, particularly in type 2 diabetes, show improved glycemic markers with pectin supplementation.

Paeoniflorin, the primary bioactive compound of Paeonia lactiflora, has demonstrated hypoglycemic properties, protective effects on pancreatic β-cells, and reduction of diabetic complications across multiple preclinical studies and early clinical investigations. A human RCT using total glucosides of peony (TGP) in diabetic kidney disease patients showed reductions in urinary albumin excretion and inflammatory biomarkers.

Perilla frutescens extracts have demonstrated hypoglycemic activity in animal models through multiple mechanisms, including improved insulin sensitivity and gut microbiome modulation in diabetic rats. The bioactive compounds rosmarinic acid, luteolin, and perillaldehyde are identified as contributing to blood glucose lowering effects. Human clinical evidence is currently limited.

Berberine, the primary alkaloid in P. amurense, has been demonstrated in multiple human randomized controlled trials to lower fasting blood glucose and HbA1c in type 2 diabetic and prediabetic populations. A landmark 2008 RCT found berberine comparable to metformin at 500 mg three times daily over three months. Meta-analyses confirm statistically significant reductions in fasting plasma glucose and 2-hour oral glucose tolerance test values.

Multiple preclinical studies demonstrate P. kurroa extracts lower blood glucose in diabetic rodent models via α-glucosidase inhibition, increased GLUT-4 translocation, and enhanced insulin secretion. Traditional Himalayan tribes have long used the root for prediabetes. No rigorous human RCTs exist yet, so evidence remains preclinical/in vitro.

Multiple RCTs and a meta-analysis of 24 trials (1,594 participants) show Pycnogenol significantly reduces fasting blood glucose and HbA1c in type 2 diabetic patients. The mechanism includes inhibition of α-glucosidase, slowing carbohydrate absorption. Clinical doses used are 50–200 mg/day.

Multiple RCTs demonstrate Pycnogenol lowers fasting plasma glucose and HbA1c in type 2 diabetes patients as an adjunct to standard therapy. A meta-analysis confirmed significant reductions in fasting blood glucose, HbA1c, and LDL-cholesterol. Mechanism involves improved endothelial function and insulin sensitivity.

Preclinical and in vitro studies demonstrate that P. integerrima gall flavonoids and pistagremic acid inhibit alpha-glucosidase, an enzyme that slows post-meal glucose absorption. A 2022 PMC study isolated six flavonoids from galls and found up to 97.65% alpha-glucosidase inhibition in vitro. Traditional Ayurvedic use for diabetes is well-documented, and these findings provide a mechanistic basis, though no human trials exist.

Evidence for plant sterols on glycemic markers is limited and mixed. The most direct signal comes from a 12-week RCT where plant sterols alone reduced TG and hs-CRP in individuals with impaired glucose regulation, but had no significant independent effect on fasting blood glucose, insulin, or HbA1c. A systematic review and meta-analysis found conflicting results across trials for blood glucose and insulin outcomes.

Multiple clinical studies demonstrate that Plantago ovata husk improves glycaemic control, including fasting glucose and HbA1c, particularly in type 2 diabetes. Psyllium's viscous gel slows gastric emptying and reduces postprandial glucose absorption. It is recognized among the FDA's five approved health benefits for psyllium fiber.

Plantago major extracts show hypoglycemic activity in multiple animal models, attributed to flavonoid compounds and insulin-stimulating effects. Plantago psyllium (P. ovata) has human clinical evidence for blood glucose lowering in type 2 diabetes as adjunct therapy, with a double-blind placebo-controlled RCT in 125 subjects. P. major has been used as a folk remedy for diabetes in Europe and Asia.

Multiple animal studies show Platycodon saponins and polysaccharides reduce fasting blood glucose, improve glucose tolerance, and modulate adipokines in diabetic and high-fat-diet models. One human RCT (NCT04023864) tested a PG extract in obese adults. Preclinical mechanistic data are strong; human evidence is limited.

Multiple preclinical studies show platycodon saponins and polysaccharides reduce fasting blood glucose, improve glucose tolerance, and modulate insulin signaling pathways. In one rat study, total saponins (200 mg/kg for 18 weeks) reduced blood sugar and improved liver function in type 2 diabetic animals. In vitro, platycodon extract enhanced insulin-stimulated glucose uptake in muscle cells.

A 2024 systematic review and dose-response meta-analysis of 25 RCTs (n=2,680) found policosanol supplementation significantly reduced fasting blood glucose. A 2023 double-blind RCT in healthy Japanese subjects (20 mg/day, 12 weeks) also demonstrated a significant reduction in glycated hemoglobin (HbA1c). Effects are statistically significant but modest in magnitude, and results across individual studies have been inconsistent.

A 2025 meta-analysis of 34 RCTs (1,500 participants) found pomegranate consumption significantly reduced fasting blood glucose, particularly in individuals with diabetes or prediabetes. Results are inconsistent across the literature; an earlier 2017 meta-analysis found no significant effect, while newer larger pooled analyses lean toward modest benefit. Effects appear greater in those with elevated baseline glucose.

Pomelo and its primary flavonoids naringenin and naringin inhibit α-glucosidase, slow carbohydrate absorption, and improve glycemic markers in preclinical models. The fruit's bioactive compounds enhance insulin secretion and improve insulin sensitivity. A clinical association between naringenin blood levels and lower insulin resistance has been reported in human observational data.

Potassium plays a mechanistic role in insulin secretion and glucose uptake, with low serum potassium linked to impaired glucose tolerance. Observational and experimental studies show that potassium deficiency reduces pancreatic beta-cell insulin release, and low potassium is associated with higher 2-hour post-load glucose levels. Evidence is primarily mechanistic and observational rather than from large interventional trials.

Human clinical trials and a 2019 systematic review (20 studies) show that Opuntia cladodes can significantly reduce fasting serum glucose and insulin, particularly in type 2 diabetic and metabolically impaired populations. The fruit alone shows less consistent benefit. Evidence quality varies and long-term effects remain unclear.

Preclinical studies show Ligustrum lucidum fruit (FLL) lowers blood glucose in normal and diabetic animal models. The primary hypoglycemic constituents identified are oleanolic acid and salidroside. No human clinical trials have confirmed these effects, so evidence is confined to animal and in vitro work.

Propionate has demonstrated dose- and context-dependent effects on blood glucose in humans. In vitro and animal studies show it suppresses hepatic gluconeogenesis via GPR43/AMPK signaling. However, a randomized placebo-controlled human study found that food-preservative-level propionate consumption acutely raised glucagon and caused insulin resistance via sympathetic nervous system activation. A 7-week human RCT using 7.5 g/day sodium propionate decreased fasting serum glucose.

Prunes have a low glycemic index (GI ≈ 29), lower than fresh plums, due to their high fiber (pectin, hemicellulose), fructose, and sorbitol content, which delay gastric emptying and blunt postprandial glucose release. Research from 2019 shows sorbitol in dried plums has glucose-lowering effects. Twice-daily snacking on prunes has been shown to decrease post-meal blood sugar levels.

Prunus domestica extracts inhibit α-amylase and α-glucosidase enzymes involved in carbohydrate digestion, reducing post-meal glucose absorption. In vitro studies show IC50 values of 7.01 mg/mL and 6.4 mg/mL respectively for these enzymes. Prunus africana has documented traditional use for diabetes mellitus and exhibits antidipeptidyl peptidase-4 (anti-DPP-4) activity in pharmacological studies.

Multiple RCTs and meta-analyses demonstrate that psyllium significantly reduces fasting blood glucose and HbA1c in people with type 2 diabetes. A 2015 meta-analysis in the American Journal of Clinical Nutrition (35 RCTs) found a mean FBG reduction of −37.0 mg/dL and HbA1c reduction of −0.97% in T2DM patients dosed before meals. Effect magnitude scales with degree of glycemic dysregulation, with little effect in euglycemic individuals. Typical effective doses range from 5–15 g/day taken before meals.

Pterocarpus marsupium has among the strongest evidence of any herbal antidiabetic agent. Multiple preclinical studies and at least one human add-on clinical trial in Type 2 diabetics demonstrate significant fasting and postprandial glucose reduction. The ICMR has previously conducted and published clinical trial results supporting its hypoglycemic activity.

Pumpkin polysaccharides, pectin, and seed extracts have demonstrated blood-glucose-lowering effects in multiple preclinical models and some human observations. Active fractions appear to stimulate pancreatic beta-cell insulin secretion and improve glucose tolerance. Clinical evidence remains preliminary but is accumulating across several Cucurbita species.

Multiple animal studies have documented hypoglycemic and antihyperglycemic properties of B. diffusa leaf and root extracts in alloxan- and streptozotocin-induced diabetic rodent models, showing reductions in fasting blood glucose and improvement in insulin and hepatic enzyme parameters. Traditional use in diabetes management is documented across several Indian communities. No well-powered human RCTs are published.

Multiple RCTs and a 2023 meta-analysis of 16 RCTs (n=1,122) found purslane significantly reduced fasting blood sugar (p<0.001) in adults, predominantly those with type 2 diabetes. HbA1c and HOMA-IR were not significantly changed in the same analysis. The omega-3 fatty acids, polysaccharides, and flavonoids in purslane are proposed mechanisms for enhancing glucose uptake and reducing glycemic stress.

Quercetin is a widely distributed flavonol with documented antidiabetic activity in preclinical studies and some clinical trials. It inhibits alpha-glucosidase, stimulates insulin secretion, and improves insulin resistance. Meta-analyses of RCTs show quercetin supplementation significantly reduces fasting blood glucose in T2DM patients.

Multiple clinical trials and a 2023 meta-analysis of seven RCTs (258 adults) found quinoa consumption significantly lowered fasting blood glucose, with optimal effects near 25 g/day. A one-year parallel RCT in impaired glucose tolerance subjects showed reduced postprandial glucose, HbA1c, and a lower conversion rate to diabetes (7.8% vs 20.3% in controls). Quinoa's low glycemic index (~53) and high fiber content contribute mechanistically.

Multiple in vitro and animal studies link radish (Raphanus sativus) to antidiabetic effects, including enhanced antioxidant defense, improved insulin sensitivity, inhibited alpha-glucosidase activity, and reduced intestinal glucose absorption. A 2017 PubMed review systematically confirmed these findings across three decades of research. Human clinical trials are still lacking, so evidence remains preclinical.

Raspberry leaf tea has demonstrated clinically significant reductions in postprandial blood glucose and insulin when consumed alongside sucrose. A 2025 randomized crossover trial in healthy adults found up to 43.6% reductions in peak glucose and sustained insulin lowering over 60 minutes. The proposed mechanism is inhibition of carbohydrate-digesting enzymes and glucose transporters by raspberry polyphenols. Effects are specific to sucrose digestion and not observed with pure glucose.

Multiple RCTs and meta-analyses report that RYR preparations reduce fasting plasma glucose, HbA1c, and insulin resistance (HOMA-IR) in subjects with metabolic syndrome. Effects are modest and typically observed alongside lipid-lowering. Mechanistic data suggest monacolin K's HMG-CoA reductase inhibition and antioxidant activity may partially protect pancreatic islets. Evidence is strongest for populations with concurrent dyslipidemia and metabolic syndrome.

Multiple preclinical and clinical studies demonstrate Rehmannia's hypoglycemic effects. The Liuwei Dihuang pill (containing Rehmannia) was tested as an adjunct to metformin in a retrospective RCT of 80 elderly type-2 diabetics, significantly lowering FPG, 2hPG, and HbA1c versus metformin alone. Animal models show Rehmannia extract reduces fasting blood glucose and improves glucose tolerance via TRPV1 and SCD1 regulation.

Rehmannia glutinosa has documented hypoglycemic effects in multiple preclinical models and one clinical retrospective study. Active compounds including catalpol, polysaccharides, and oligosaccharides reduce fasting blood glucose and improve glucose tolerance. A 2023 retrospective clinical trial found the Liuwei Dihuang formula (rehmannia-based) significantly lowered FPG, 2hPG, and HbA1c as an adjunct to metformin in elderly T2DM patients.

Animal data consistently show reishi polysaccharides lower fasting plasma glucose and HbA1c via insulin secretagogue and insulin-sensitising mechanisms. A 2005 human RCT in 71 type-2 diabetic patients found 5,400 mg/day Ganopoly for three months reduced HbA1c compared to placebo. However, a Cochrane systematic review (2015) of five RCTs found no statistically significant reduction in HbA1c, total cholesterol, or fasting glucose, flagging high or unclear risk of bias.

Resveratrol, a polyphenol found in grapes and berries, has been evaluated in multiple RCTs for glycemic control in T2DM. A meta-analysis of 15 RCTs (896 T2DM patients) found resveratrol significantly improved insulin resistance (HOMA-IR, WMD: −0.99, p=0.002). It activates SIRT1 and AMPK pathways to enhance insulin sensitivity.

Rhubarb's anthraquinones—emodin and rhein—have demonstrated antidiabetic effects in preclinical and early clinical studies. Active compounds inhibit intestinal alpha-glucosidase activity, improve insulin resistance, and reduce fasting blood glucose. An RCT in CKD patients showed significant reduction in fasting and postprandial blood glucose alongside rhubarb supplementation.

Human clinical data from a randomized trial in type 2 diabetic patients showed significant reductions in fasting blood glucose and HbA1c after one month of rhubarb extract. Proposed mechanisms include insulin secretagogue effects and flavonoid (quercetin)-mediated glucose metabolism modulation.

Robusta coffee contains higher concentrations of chlorogenic acids than arabica, and chlorogenic acids have demonstrated inhibition of intestinal glucose absorption and alpha-glucosidase activity in human subjects. A clinical study of robusta coffee at different roast levels measured direct postprandial blood glucose response in ten healthy volunteers, with light-roasted robusta showing greater glycemic-modifying activity. Chlorogenic acids inhibit glucose-6-phosphatase, curtailing hepatic glucose output.

Rosehip (Rosa canina) extracts have shown reductions in fasting blood glucose and HbA1c in several RCTs, particularly in overweight or obese individuals. A 2023 systematic review of RCTs found significant reductions in fasting blood glucose and HbA1c with rosehip supplementation, though results were mixed across studies. The mechanism involves modulation of peroxisome proliferator-activated receptors and antioxidant-mediated improvement in insulin sensitivity.

Animal studies robustly demonstrate that rose hip prevents and reverses diet-induced glucose intolerance and reduces blood glucose and insulin levels in high-fat-fed mice through downregulation of hepatic lipogenic pathways. A human RCT in 31 obese subjects did not find significant effects on glucose tolerance or glycated hemoglobin, though tiliroside (a rose hip flavonoid) activates adiponectin signaling relevant to glucose metabolism.

Human clinical trials show rosemary supplementation can reduce fasting blood glucose and HbA1c, particularly in diabetic patients. Mechanistic studies identify AMPK and PPAR pathway activation by rosemary extract as key drivers of improved glucose metabolism. Evidence is early-stage with some trials showing only modest benefit independent of lifestyle changes.

Rosmarinic acid has demonstrated hypoglycemic and glucose-regulatory effects in multiple preclinical models including STZ-induced type 1 diabetic rats and high-fat-diet-induced type 2 diabetic rats. Mechanisms include upregulation of GLUT4 expression in muscle and downregulation of hepatic PEPCK, reducing gluconeogenesis. Human clinical data are limited, but RA's effects on glucose homeostasis are robustly documented at the preclinical level.

Multiple RCTs and a systematic review indicate RJ can modestly reduce fasting blood glucose and HbA1c in type 2 diabetic patients, particularly with ≥8-week interventions. A 2023 meta-analysis of 10 RCTs found subgroup significance in non-healthy populations. Effect sizes are small and overall evidence quality is rated low.

Alcoholic extracts of R. cordifolia have demonstrated antidiabetic activity in alloxan- and STZ-induced diabetic rat models, reducing blood glucose levels. A rat study also showed that R. cordifolia attenuated diabetic neuropathy through antidiabetic and antioxidant mechanisms. Human clinical trials are absent.

A double-blind, placebo-controlled RCT in type 2 diabetes patients found 500 mg/day rutin for three months reduced fasting blood glucose, insulin, and HbA1c, and improved insulin sensitivity markers HOMA-IR and QUICKI. A separate trial using rutin combined with vitamin C found modest reduction in fasting blood glucose percentage change.

A 2025 systematic review and meta-analysis of 31 RCTs found that rye consumption significantly reduces the area under the insulin curve without affecting glucose indices, consistent with a 'rye factor' of lowered postprandial insulinemia. Individual RCTs show rye-based foods produce lower postprandial insulin responses than refined wheat at comparable carbohydrate loads. The evidence for blood glucose reduction per se is weaker.

An 8 g/day safflower oil trial in 35 obese post-menopausal women with type 2 diabetes (16 weeks, crossover design) reduced HbA1c by 0.64% and improved insulin sensitivity. A separate clinical trial in 67 metabolic syndrome patients found improved insulin resistance with 8 g/day for 12 weeks. Animal studies show significant hypoglycemic effects at 200–300 mg/kg doses.

Multiple RCTs and meta-analyses demonstrate that saffron supplementation significantly reduces fasting plasma glucose (FPG) and HbA1c in patients with type 2 diabetes. A 2024 systematic review and meta-analysis confirmed these glycemic benefits. Effects on insulin resistance (HOMA-IR) are less consistent across studies. Typical doses studied are 100 mg/day of saffron powder for 8–12 weeks.

Multiple clinical trials in type 2 diabetic patients show Salvia officinalis leaf extract reduces fasting and postprandial blood glucose. A 2022 systematic review and meta-analysis confirmed positive effects on glycemic status. Proposed mechanisms include PPARγ agonism and inhibition of hepatic gluconeogenesis.

Smilax glabra has demonstrated hypoglycemic activity in murine studies, and a PMC review confirms that S. glabra 'was shown to lower blood glucose.' Flavonoid fractions and ethyl acetate extracts showed significant blood glucose reduction in animal models. The evidence is preclinical; no human blood sugar trials have been completed.

A 12-week randomized, double-blind, placebo-controlled trial in 80 hyperglycemic subjects found an Omija (schisandra) extract mixture significantly decreased fasting plasma glucose, postprandial glucose, insulin AUC, and fructosamine versus placebo. In TCM schisandra has historically been listed for diabetes. Preclinical studies support alpha-glucosidase inhibition and improved pancreatic function.

A 12-week RCT in 28 women found that 6.7 g/day of Schisandra supported healthier blood sugar alongside improvements in triglycerides and liver enzymes. Preclinical data indicate schisandrins are hypoglycemic agents that facilitate glucose transport and metabolism via GLUT-2 activation. Human evidence is limited to a single small trial.

Preclinical studies show Poria cocos sclerotium extracts and their triterpenes lower blood glucose in diabetic mouse models. The mechanism involves insulin sensitizer activity via specific triterpenoid compounds. Human clinical trials are not yet published.

Multiple in vitro and animal studies have demonstrated hypoglycemic and insulin-sensitizing properties of Scrophularia ningpoensis root extracts. An aqueous extract improved insulin sensitivity via AMPK-mediated suppression of the NLRP3 inflammasome in diabetic (db/db) mice. Iridoid glycosides from the genus have also shown protective effects on pancreatic beta-cell function. Human clinical evidence remains absent.

SDG has demonstrated antihyperglycemic effects across multiple animal diabetes models, reducing blood glucose and improving insulin and C-peptide levels. A human crossover RCT in type 2 diabetics using 600 mg SDG/day for 3 months showed decreased fasting plasma glucose and HbA1c prior to multiple comparison correction. Mechanistically, SDG reduces oxidative stress that underlies beta-cell damage and enhances insulin signaling via GLUT4 upregulation.

Clinical trials and meta-analyses demonstrate that sesame reduces fasting blood glucose and HbA1c, particularly in type 2 diabetes populations. A meta-analysis of 13 RCTs found fasting glucose reduction of −28.48 mg/dL and HbA1c reduction (WMD −0.98%) with sesame supplementation. Sesame's flavonoids, phenolic compounds, and fiber are proposed to protect pancreatic beta cells and slow glucose absorption.

A 2020 in vitro study directly on Rumex acetosella found that ethanol and ethanol-water extracts inhibited α-glucosidase more potently than the reference drug acarbose, suggesting antihyperglycemic potential. This is preclinical only—no human trials have been conducted.

Shiitake beta-glucans inhibit intestinal alpha-glucosidase and reduce glucose transport across intestinal epithelial cells in vitro. A 12-week human RCT using a shiitake-containing mixture showed significantly reduced fasting insulin and HOMA-IR in prediabetic adults versus placebo. Most mechanistic data are preclinical; isolated shiitake human trials are limited.

Hydroxy-α-sanshool and other Z. bungeanum compounds (hyperoside, quercetin, beta-sitosterol) demonstrate antidiabetic effects in rodent models by improving insulin sensitivity, increasing hepatic glycogen synthesis, and reducing blood glucose. Network pharmacology and molecular docking studies have characterised the multi-target antidiabetic mechanism. No human RCT data.

Multiple RCTs and meta-analyses demonstrate that silymarin significantly lowers fasting blood glucose and HbA1c in type 2 diabetes patients. A 2021 meta-analysis of 7 RCTs (350 patients) found significant reductions in FBS and HbA1c. A 2024 dose-response meta-analysis of 33 trials (1,943 participants) confirmed a mean FBG reduction of approximately 21.7 mg/dL vs. placebo. Effects appear most robust as adjunctive therapy alongside standard hypoglycemic agents.

Preclinical studies show that P. hydropiper extracts significantly inhibit alpha-amylase activity, a key enzyme in carbohydrate digestion, suggesting a mechanism for blood glucose modulation. Hypoglycemic activity has been documented in animal models. No human clinical trials have been performed.

Multiple Smilax species (S. glabra, S. china, S. canellifolia, S. perfoliata) have demonstrated blood-glucose-lowering effects in alloxan- and streptozotocin-induced diabetic rodent models. Smilax glabra ethyl acetate extract reduced blood glucose to physiological levels in diabetic mice after two weeks. The mechanism appears insulin-dependent, suggesting an insulin-sensitising rather than secretagogue action.

Multiple in vitro and animal studies show Polygonatum polysaccharides, saponins, and flavonoids lower blood glucose, improve insulin sensitivity, and inhibit alpha-glucosidase. A 2013 mouse study (PMC3843710) found Rhizoma Polygonati Odorati extract blocked weight gain and reduced fasting blood glucose in high-fat-diet animals. Human-level evidence remains preliminary; no large RCT has been completed.

S. flavescens is documented in Chinese folk and institutional medicine for type 2 diabetes management. Flavonoids including quercetin glycoside inhibitors reduce blood glucose. S. flavescens EtOAc extract significantly decreased fasting blood glucose in T2DM rats, and S. japonica extract reduced blood glucose in high-fat diet models.

Soursop extracts inhibit the carbohydrate-digesting enzymes α-glucosidase and α-amylase, reducing postprandial glucose absorption. In vivo rodent studies show decreased fasting blood glucose, increased insulin, and improved lipid profiles. One clinical study found a positive adjuvant effect of A. muricata alongside glibenclamide in type 2 diabetes patients.

Soy protein supplementation significantly reduces fasting plasma glucose, fasting serum insulin, and HOMA-IR in patients with type 2 diabetes and metabolic syndrome, per meta-analyses of RCTs. Soy isoflavones modulate glucose metabolism via estrogen receptor and AMPK pathways.

Multiple RCTs and meta-analyses indicate soy isoflavones can modestly improve fasting glucose and insulin levels, particularly in individuals with metabolic syndrome or prediabetes. Effects appear strongest with whole soy versus isolated isoflavones. Results across studies are heterogeneous.

Soy protein and isoflavones have been studied for effects on fasting glucose and insulin in individuals with type 2 diabetes and metabolic syndrome. A meta-analysis of 11 studies found soy protein could lower fasting glucose, insulin, and HOMA-IR in patients with type 2 diabetes and metabolic syndrome, though results are inconsistent across studies. Benefits appear most consistent in individuals with elevated baseline glucose or metabolic dysfunction.

Spearmint (Mentha spicata) extracts have demonstrated hypoglycemic activity in animal models of diabetes. Polyphenols and flavonoids in the leaf, including rosmarinic acid, are considered the active constituents. Human clinical evidence remains limited to preclinical data, though the plant has long-standing traditional use for blood sugar support.

Multiple preclinical studies and one meta-analysis of RCTs support blood glucose-lowering activity for S. indicus. Rodent studies show significant reductions in blood glucose in streptozotocin-induced diabetic models, with improved hepatic glycogen and plasma insulin. In human studies (as part of the Meratrim blend), blood glucose was improved in obese subjects.

Spinach thylakoids suppress postprandial blood glucose elevation by slowing fat and carbohydrate digestion, and spinach extracts show insulin-sensitizing properties in preclinical and early clinical work. Thylakoids have also been shown to prevent postprandial hypoglycaemia following high-carbohydrate meals in overweight women.

A meta-analysis of 8 RCTs in type 2 diabetes patients found spirulina supplementation produced a significant reduction in fasting blood glucose (−17.88 mg/dL, 95% CI: −26.99, −8.78). Clinical trials also show reductions in post-prandial blood glucose and insulin sensitivity improvements, though effects on HbA1c are inconsistent. Proposed mechanisms include inhibition of alpha-glucosidase and alpha-amylase, as well as AMPK-mediated GLUT4 upregulation in skeletal muscle.

SPMs improve insulin sensitivity, reduce pancreatic islet inflammation, and counter diabetic complications including nephropathy and neuropathy. Human clinical trials suggest SPM precursors reduce inflammation and pain in diabetic patients. Reduced SPM biosynthesis has been documented in human type 2 diabetes.

A 2024 meta-analysis of 26 studies (n=1,439) found low-certainty evidence that stevia significantly reduced blood glucose levels (WMD: −3.84; 95% CI: −7.15, −0.53; p=0.02), particularly in individuals with higher BMI, diabetes, or hypertension. Effects were most pronounced with consumption under 120 days. Results are inconsistent across trials, with some well-controlled RCTs showing no significant effect on fasting blood sugar or HbA1c at moderate doses.

Multiple meta-analyses of RCTs demonstrate that steviol glycosides (SGs) produce a statistically significant reduction in fasting blood glucose (FBG) in adults. A 2024 meta-analysis of 12 RCTs (n=871) found a mean FBG reduction of −4.10 mg/dL vs. control. Effects on HbA1c are not statistically significant, and overall evidence quality is rated low to moderate.

Stigmasterol improves glucose homeostasis through multiple mechanisms including enhanced GLUT4 translocation, protection of pancreatic β-cells from glucolipotoxicity, and reduction of fasting blood glucose. Preclinical studies in diabetic mouse models show significant improvements in oral glucose tolerance. Evidence is restricted to in vitro and animal models; no human clinical trials have been completed.

Strawberry polyphenols inhibit carbohydrate-digesting enzymes and improve insulin signaling, with several RCTs showing improved insulin sensitivity or reduced postprandial glycemia. A 2025 RCT in prediabetic adults found that 12 weeks of 2.5 daily servings of strawberries improved prediabetes status and cardiometabolic markers. A combined strawberry-and-cranberry polyphenol RCT demonstrated improved whole-body insulin sensitivity via euglycemic clamp.

Animal studies using heat-killed S. thermophilus in type 2 diabetic rat models have demonstrated reductions in fasting blood glucose, glucose intolerance, HbA1c, fasting insulin, and HOMA-IR. Human clinical evidence using S. thermophilus specifically for blood sugar is limited, appearing within combination probiotic trials rather than standalone studies.

Multiple human RCTs demonstrate sulforaphane reduces fasting blood glucose and HbA1c in type 2 diabetes patients. It activates PI3K/AKT and AMPK pathways to enhance insulin signaling and suppress hepatic glucose production. The 2017 Science Translational Medicine trial is the landmark clinical study.

Human trials in type 2 diabetic patients show sunflower seeds significantly reduce fasting blood glucose. A 6-month controlled study in 60 T2D patients found fasting glucose dropped from 186 to 110 mg/dL in the sunflower group versus a smaller reduction in controls. Chlorogenic acid in sunflower seeds is identified as a key antidiabetic bioactive.

Multiple preclinical studies demonstrate antidiabetic activity of A. calamus extract in STZ-induced and genetically diabetic (db/db) mouse models, through mechanisms including α-glucosidase inhibition, insulin sensitization, and GLP-1 modulation. Traditional use for diabetes is documented in American, Indonesian, and Ayurvedic folk medicine.

Multiple preclinical studies demonstrate significant hypoglycemic activity of Swertia chirayita extracts and isolated compounds, particularly the xanthone swerchirin and mangiferin. Animal models show blood glucose reduction comparable to reference antidiabetic drugs. A small clinical evaluation in diabetic patients also reported lowered serum glucose levels. Human trial data remain limited but the pharmacological evidence is substantial.

Multiple RCTs and a 2025 systematic review and meta-analysis confirm taurine supplementation significantly reduces fasting blood glucose, HbA1c, fasting insulin, and HOMA-IR in populations including type 2 diabetics. Plasma taurine is consistently lower in individuals with T2DM. Effects on fasting glucose are modest but statistically significant.

T. chebula has documented antidiabetic activity in animal models and limited human trials. A prospective randomized double-blind placebo-controlled study (n=60 type 2 diabetic patients) evaluated aqueous T. chebula extract at 250 mg and 500 mg twice daily for 12 weeks, assessing endothelial function and oxidative stress biomarkers. A combination formula clinical trial also demonstrated reduced fasting blood glucose in hyperlipidemic type 2 diabetic women.

THIAA (META060) supplementation in HFD-fed obese/diabetic mice for 8 weeks reduced glucose intolerance and fasting hyperinsulinemia, and improved glucose homeostasis. Related iso-alpha acids have shown similar effects in human interventional data. THIAA may activate PPARα/γ pathways that influence glucose metabolism in adipocytes.

Threonic acid improved glycemic control in diet-induced obese mice when combined with intermittent fasting, in addition to its appetite-suppressing effects. This was demonstrated in a 2026 study in a high-impact peer-reviewed journal. Evidence is preclinical only.

Multiple clinical and preclinical studies demonstrate T. cordifolia reduces fasting blood glucose and improves insulin sensitivity in type 2 diabetics. A randomized add-on trial in 100 T2DM patients (500 mg TID) showed significant glycemic improvement. Mechanistically, the diterpenoid tinosporaside promotes GLUT4 translocation via PI3K/AMPK pathways, stimulates insulin secretion, and inhibits gluconeogenesis.

Epidemiological data and metabolomics studies link higher circulating TMG levels with lower insulin resistance and reduced type 2 diabetes risk. A randomized clinical trial in prediabetic adults showed TMG reduced insulin area under the curve during an oral glucose tolerance test, though it did not improve insulin sensitivity measured by euglycemic hyperinsulinemic clamp. Animal data is supportive but human clinical evidence remains limited and mixed.

Clinical RCTs in T2DM patients show tocotrienols can improve fasting blood glucose, HbA1c, and HOMA-IR. A 24-week double-blind RCT with annatto delta-tocotrienol demonstrated significant reductions in fasting blood glucose, HbA1c, and insulin resistance scores. A second RCT in T2DM subjects found improved fasting blood sugar and redox balance.

A clinical RCT found an 8-week tomato-rich diet significantly reduced fasting blood glucose in overweight postmenopausal women versus controls. Lycopene has also demonstrated anti-diabetic effects in animal models via reduction of oxidative stress-driven insulin resistance, though human clinical evidence remains limited.

Multiple preclinical studies show trans-pterostilbene improves glycemic control by activating the PI3K/Akt signaling pathway, enhancing peripheral glucose uptake, and reducing oxidative stress in diabetic animal models. Human-specific data remain limited, but the mechanistic evidence is robust. Doses of 20–40 mg/kg in rodents consistently lowered fasting glucose and HbA1c.

Two randomized controlled trials in diabetic women found tribulus extract significantly lowered fasting blood glucose, post-prandial glucose, and HbA1c compared to placebo. Effects on lipids (LDL and total cholesterol reduction) were also observed. Evidence is limited to female diabetic populations.

In obese and diabetic animal models, tributyrin consistently lowers fasting blood glucose and improves glucose tolerance. Effects are linked to reduced adipose inflammation, hepatic steatosis attenuation, and GPR109A activation. Evidence is entirely preclinical.

Trichosanthes kirilowii root is one of the oldest recorded TCM treatments for the 'Xiaoke' (wasting-thirst) syndrome corresponding to diabetes, with use documented in the Shennong Bencao Jing. Modern preclinical and translational research confirms hypoglycemic activity via insulin receptor activation and glycan-mediated pathways. A retrospective cohort study found TK was the most frequently used Chinese herb among type 2 diabetic patients in Taiwan, and animal studies consistently demonstrate dose-dependent blood glucose reduction.

Multiple RCTs and a 2021 systematic review (12 studies, 749 patients) show Triphala significantly reduces fasting blood glucose and HbA1c in diabetic patients, though not in normoglycemic individuals. Mechanisms include enhanced insulin sensitivity via PPAR pathways. Evidence is primarily in type 2 diabetic populations.

Substantial meta-analytic evidence from RCTs demonstrates that turmeric/curcumin supplementation significantly lowers fasting blood glucose and HbA1c in patients with type 2 diabetes and metabolic syndrome. One meta-analysis of 18 RCTs (1,382 T2D patients) found curcumin reduced FBG by −11.48 mg/dL and HbA1c by −0.54%. Effects on insulin resistance (HOMA-IR) are also reported.

Multiple meta-analyses of RCTs show CoQ10 supplementation modestly reduces fasting blood glucose and HbA1c across diabetic and metabolic syndrome populations. An umbrella review published in 2024 found mean differences in fasting blood glucose ranging from −5.2 to −11.21 mg/dL. The mechanism involves improved mitochondrial function and reduction of oxidative-stress-driven insulin resistance.

Multiple short-term human clinical trials demonstrate that vanadyl sulfate and other vanadium salts reduce fasting blood glucose in type 1 and type 2 diabetes patients. Mechanistically, vanadium acts as an insulin mimetic by inhibiting protein tyrosine phosphatase 1B (PTP1B) and activating downstream insulin signaling. Effects are modest compared to animal models and no long-term human safety data exists.

Vanadyl sulfate is the most studied form of vanadium for blood sugar support. Small human trials report improvements in hepatic and skeletal muscle insulin sensitivity in T2DM patients. It acts as an insulin mimetic. Evidence is preliminary and safety concerns limit widespread use.

Thiamine is an essential cofactor in glucose metabolism, and people with diabetes frequently show lower thiamine status due to accelerated renal excretion. Clinical trials suggest high-dose thiamine supplementation may reduce markers of diabetic complications and help protect endothelial function in hyperglycemic patients. A Cochrane review identified a potential link between thiamine and lower albuminuria in diabetic kidney disease.

Nicotinic acid (high-dose niacin) is well-documented to raise blood glucose and HbA1c in patients with type 2 diabetes and dyslipidemia, representing an adverse metabolic effect at pharmacological doses. In contrast, niacinamide at physiological to moderate doses has not consistently shown problematic glucose effects and has been studied for potential beta-cell protection in type 1 diabetes prevention. The relationship is therefore bidirectional and form/dose-dependent.

PLP, the active coenzyme form of vitamin B6, participates in roughly 150 enzymatic reactions central to carbohydrate metabolism and inhibits formation of advanced glycation end-products (AGEs). Small clinical trials show pyridoxine supplementation can lower postprandial blood glucose in healthy individuals and improve glycaemia as adjuvant therapy in type 2 diabetes.

Multiple RCTs and meta-analyses have examined vitamin E's effect on glycemic indices in diabetic patients. A 2023 meta-analysis of 38 RCTs found significant reductions in HbA1c, fasting insulin, and HOMA-IR, though fasting blood glucose reduction was not statistically significant. Results are heterogeneous and dependent on dose, duration, and patient population.

In diabetic rodent models, wasabi-derived allyl isothiocyanate reduced blood glucose and increased glucose transporter-2 expression and insulin receptor substrate-1, while activating Nrf2 and downregulating NF-κB in liver and kidney. A separate study found wasabi powder preserved renal function in type 2 diabetic mice. Human clinical evidence for glycemic effects is absent; evidence is preclinical.

Wheat's dietary fiber components—particularly arabinoxylan (AX)—slow glucose absorption in the small intestine and reduce postprandial blood glucose. Multiple RCTs and meta-analyses confirm reductions in fasting glucose and HbA1c with high-fiber wheat-based diets. Effects are more pronounced for soluble fiber and intact grain structures than for refined wheat or finely ground bran.

Multiple animal studies show wheatgrass lowers blood glucose, raises insulin levels, and restores key carbohydrate-metabolizing enzyme activities in diabetic models. Human evidence is limited to a small Ayurvedic clinical study; no large human RCT has confirmed these effects. Evidence is primarily preclinical with traditional use context.

Whey protein consumed before or with meals consistently lowers postprandial blood glucose via stimulation of GLP-1, GIP, and insulin secretion while slowing gastric emptying. A systematic review and meta-analysis of 16 RCTs (244 individuals) confirmed significant reductions in postprandial glucose across lean, obese, and type 2 diabetic populations. A 2025 Diabetes Care RCT demonstrated premeal whey (20–30 g) dose-dependently reduced glucose peaks in women with gestational diabetes.

Dioscoretine, a compound present in Dioscorea tubers, demonstrated hypoglycemic activity in normal and alloxan-diabetic rabbits in animal studies. Dioscorin protein from other Dioscorea species has shown antidiabetic effects in rodent models. A small human clinical trial found antioxidant properties and raised HDL in elderly adults, but direct blood sugar data in humans remain very limited.

An in vitro study (Paun et al.) demonstrated that Betonica officinalis polyphenolic-rich extracts inhibit alpha-amylase and alpha-glucosidase enzymes linked to postprandial blood glucose, revealing anti-diabetic potential for the first time. Evidence is preclinical only.

Multiple in vitro and animal studies demonstrate antidiabetic properties of X. strumarium. Caffeoylquinic acid derivatives, particularly methyl-3,5-di-caffeoyquinic acid, significantly inhibit α-glucosidase and PTP1β enzymes relevant to blood glucose control. In alloxan-induced diabetic mouse models, ethyl acetate fractions of X. strumarium significantly lowered blood glucose levels.

Clinical trials show XOS can lower blood glucose and HbA1c in type 2 diabetic patients and reduce glycemic response in healthy adults. A randomized double-blind trial in 26 T2DM subjects found 4 g/day XOS for 8 weeks reduced glucose, HbA1c, and fructosamine. XOS added to sucrose significantly lowered the glycemic index in healthy adult volunteers.

D-xylose selectively inhibits intestinal sucrase, slowing sucrose hydrolysis and blunting postprandial blood glucose rises. A randomized double-blind crossover trial in Korean subjects (normal and prediabetic) found significant reductions in serum glucose at 30 min post-consumption with xylose-supplemented drinks. Rodent studies confirm suppression of hepatic gluconeogenesis via PEPCK downregulation and enhanced peripheral glucose uptake.

Preclinical studies, including a 2020 PMC-published animal study, show yarrow hydroalcoholic extract significantly reduces blood glucose in streptozotocin-induced diabetic rats, performing comparably to metformin. Mechanistic work identifies alpha-glucosidase inhibition, insulin sensitization, and insulin secretagogue activity. No controlled human trials exist.

Multiple randomized controlled trials demonstrate that brewer's yeast supplementation significantly reduces fasting blood glucose and HbA1c in patients with type 2 diabetes. The primary mechanism involves chromium-containing glucose tolerance factor (GTF), which potentiates insulin receptor binding. Typical study doses range from 1,800 mg/day for 8–12 weeks.

Yellow Root contains berberine, for which there is robust clinical evidence of blood-glucose-lowering effects in type 2 diabetes and prediabetes. Multiple meta-analyses of RCTs confirm reductions in fasting plasma glucose, postprandial glucose, and HbA1c. Yellow Root was also traditionally used in the southern US as a folk remedy for diabetes.

Human trials and a 2025 systematic review/meta-analysis show yerba mate can reduce postprandial glucose, HbA1c, and HOMA-IR, particularly in people with pre-diabetes or impaired fasting glucose. Effects on fasting glucose in healthy subjects are less consistent. The strongest signals are in glycemic-compromised populations.

Animal studies demonstrate that yucca schidigera extract lowers blood glucose in diabetic rats and modulates glucose homeostasis. A 2017 study found yucca enhanced the antioxidant defense system in diabetic rats, improving blood sugar and metabolic function. Saponins have demonstrated hypoglycemic effects across species. No human RCT for blood sugar exists; evidence is animal-only.

Multiple preclinical studies across several Zanthoxylum species demonstrate hypoglycemic activity. Extracts inhibit α-glucosidase and α-amylase enzymes, reduce fasting blood glucose in alloxan- and streptozotocin-induced diabetic rodents, and protect pancreatic β-cells. No human clinical trials have been conducted to date.

Zinc is involved in virtually all aspects of insulin metabolism including synthesis, secretion, and utilization of insulin. Meta-analyses show zinc supplementation can improve glycemic parameters in T2DM. It also has a protective effect against pancreatic beta-cell destruction.

Preclinical animal research has investigated L-tartaric acid's antihyperglycemic potential. In a streptozotocin-induced diabetic rat model, L-tartaric acid at 40 mg/kg significantly reduced blood glucose, improved oral glucose tolerance, and increased liver and muscle glycogen content. No human clinical trials have reproduced or validated these findings.

A. spectabilis is used as a traditional medicine for hypoglycemic (blood sugar-lowering) conditions in Himalayan folk medicine, documented in multiple ethnobotanical surveys. Diabetes is explicitly listed among traditional indications. Preclinical hypoglycemic activity has been reported in pharmacological review literature.

In the 1940s, adrenal cortex extract was used by physicians for 'hypoadrenal syndrome' that included hypoglycemia (low blood sugar) as a key symptom. Cortisol is a known counter-regulatory hormone that raises blood glucose via gluconeogenesis. No modern clinical trial has examined adrenal cortex supplements specifically for blood sugar regulation.

Allspice has a long-documented traditional use for managing high blood sugar and diabetes in Caribbean and Central American folk medicine. Phytochemical reviews note hypoglycemic activity among allspice's reported biological properties, attributed in part to eugenol's potential protective effect on pancreatic islet cells. No human clinical trials have confirmed this effect.

In animal models (glucose-fed rats), argan oil significantly reduced blood glucose, hyperglycemia, and insulin resistance through antioxidant mechanisms. Human evidence from type-2 diabetic RCTs did not specifically measure glycaemic outcomes as primary endpoints.

Bacopa has been used in Ayurveda to help control blood sugar levels for centuries. Preclinical studies in diabetic rodent models show significant glucose-lowering and HbA1c-normalizing effects. No rigorous human clinical trials have yet confirmed these antihyperglycemic effects, so the relationship remains at the traditional/preclinical level.

Multiple rodent studies demonstrate that beta-sitosterol lowers fasting blood glucose, reduces HOMA-IR, and improves oral glucose tolerance in high-fat diet and streptozotocin-induced type-2 diabetic models, partly through upregulation of PPARγ and GLUT4. Effects have been observed at doses of 15–25 mg/kg body weight over 30-day interventions in rats. No human clinical trials specifically targeting glycemic control have been published.

Animal studies and review literature note hypoglycemic effects of black walnut and related Juglans species, attributed to juglone and quercetin-3-O-glucoside content. Evidence in humans is lacking. A review in the African Journal of Traditional, Complementary, and Alternative Medicine documented the hypoglycemic effect in diabetic rats.

Fucoidan and phlorotannins from bladderwrack inhibit alpha-glucosidase and may lower postprandial glucose in cell and animal models. Fucoidan supplementation in a 30-person human study on metabolic syndrome improved insulin sensitivity, though evidence for bladderwrack specifically as a whole herb in humans remains preliminary.

In glandular therapy—a naturopathic and early 20th-century European biological medicine tradition—bovine pancreas was used for both digestive and endocrine (blood sugar) support, based on the 'like supports like' principle that organ consumption nourishes the corresponding organ. Historically, bovine pancreas was the original source from which insulin was purified in 1921, establishing a scientific precedent for its endocrine relevance, though this involved injected purified hormone, not oral glandular supplements. No human clinical evidence supports oral bovine pancreas supplements for blood sugar regulation.

Animal studies demonstrate that caraway aqueous extract and oil reduce fasting blood glucose in streptozotocin-induced diabetic rodent models. Human evidence is inconsistent, with some human studies showing benefit and others showing no significant effect on fasting blood glucose. The evidence is insufficient to confirm a scientific-level clinical effect in humans.

Cellulase is sometimes proposed to support blood sugar balance through hydrolysis of cellulose to glucose, providing a slow-release energy substrate. A 1983 Russian study (Probl Endokrinol) cited in the secondary literature reported blood-glucose-lowering effects of dietary supplements with varying cellulose content in type 2 diabetics. This represents very old, low-quality, and non-isolatable evidence; no modern RCT has tested cellulase supplementation specifically for blood sugar outcomes in humans.

A. bisporus has shown antidiabetic effects in multiple animal models, including reduced plasma glucose in streptozotocin-induced diabetic rats and improved glucose clearance in ovariectomized mice. The mechanisms involve insulin sensitization and hepatic glucose regulation. No controlled human clinical trials for glycemic outcomes have been published.

Animal studies show M. pruriens seed extract has antihyperglycemic effects in alloxan-induced diabetic rats, with dose-dependent glucose reductions up to 55%. In vitro assays show alpha-amylase and alpha-glucosidase inhibition. Human clinical evidence is absent; reviewers note more studies are needed.

Sambucus nigra extracts exhibit alpha-glucosidase and alpha-amylase inhibitory activity in vitro, and animal models show blood glucose reduction and improvement in insulin resistance. One study found elderberry extract stimulated glucose uptake in adipocytes. Traditional use includes elder as part of anti-diabetic herbal regimens. No human clinical trials specifically assessing glycemia are available.

Gentiana scabra root extract has been shown to boost GLP-1 secretion and lower blood glucose in diabetic db/db mice in a preclinical study. Traditional Korean medicine uses Gentiana scabra for diabetes. The broader Gentianaceae family, including Swertia chirayita, has traditional hypoglycemic use across Asian medicine systems. Human clinical data are absent.

Animal studies suggest guggulsterones exert hypoglycemic and insulin-sensitizing effects. An antidiabetic effect has been noted in high-fat diet-induced diabetic rats. No well-designed human clinical trials for blood sugar management with guggul alone have been published.

Native American groups used huckleberry leaves and berries as a folk remedy for regulating blood sugar, a use corroborated by folk records for closely related Vaccinium species. Leaf teas containing glucoquinones and tannins were traditionally taken to reduce glycosuria and hyperglycemia. Clinical evidence exists for related Vaccinium species (bilberry, whortleberry), but huckleberry itself has not been subjected to high-quality clinical trials for blood sugar control.

C. citratus is widely used in traditional medicine for diabetes management. Animal models show hypoglycemic effects of citral, lemongrass essential oil, and aqueous extracts, with reductions in blood glucose, insulin, and triglycerides. Human clinical evidence for glycemic control is lacking; effects in rodent models are inconsistent depending on the degree of beta-cell destruction.

Rhodiola rosea has demonstrated blood glucose-lowering effects in multiple pre-clinical models, including reduction of fasting blood sugar, improved insulin response, and modulation of the gut microbiome in diabetic mice. Human clinical trials are planned but not yet completed. The traditional use for metabolic and energy balance supports inclusion, but clinical evidence remains pre-clinical only.

Suma is listed in traditional Brazilian folk medicine as an antidiabetic agent. Cell studies show that ecdysteroids from Pfaffia species increased hepatic glucose utilization by 44–77% in vitro, providing biochemical rationale. It has been described as hypoglycemiant in X-ray fluorescence characterization studies. No human clinical trials confirm antidiabetic efficacy.

Sweet wormwood has a traditional record of use for blood sugar management, supported by animal studies and a small published case series. Controlled human clinical trials are lacking. Animal and in vitro work identifies DPP-IV inhibition and improved insulin signaling as plausible mechanisms.

Tongkat Ali is documented in traditional Southeast Asian medicine for the treatment of diabetes and blood sugar regulation. NIH LiverTox notes its traditional use for diabetes alongside other conditions. Preclinical animal studies demonstrate antihyperglycemic activity. One human RCT noted decreased glucose in stressed subjects taking TA with multivitamins, but no dedicated human clinical trial in diabetic patients has been conducted. Blood sugar evidence is primarily traditional and preclinical.

Traditional Indian medicine uses MP for diabetes management. In vitro studies show MP seed extracts inhibit alpha-amylase and alpha-glucosidase. Multiple rodent studies confirm significant, dose-dependent hypoglycemic effects. A 2025 systematic review and meta-analysis of 13 animal studies confirmed significant glucose reduction (SMD −18.36) and regenerative pancreatic effects. No dedicated human clinical trial for glycemic control has been published.

Watercress has extensive documented traditional use as an antidiabetic agent in Iranian, Moroccan, and other folk medicine systems. Preclinical evidence in diabetic rats demonstrates significant hypoglycemic effects from watercress extract. No confirmed large-scale human RCT specific to blood glucose control has been published.

Waterhyssop has a documented traditional use in Ayurveda for controlling blood sugar levels, and preclinical evidence supports antihyperglycemic activity. A randomized experiment in prediabetic individuals with bacoside-A suggested potential, though robust human RCT evidence remains limited.